

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER 7

WO 9605181A1

(51) International Patent Classification ⁶ : C07D 265/32, 413/06, A61K 31/535	A1	(11) International Publication Number: WO 96/05181
		(43) International Publication Date: 22 February 1996 (22.02.96)

(21) International Application Number: PCT/GB95/01868

(22) International Filing Date: 7 August 1995 (07.08.95)

(30) Priority Data:

9416427.4	15 August 1994 (15.08.94)	GB
9509605.3	11 May 1995 (11.05.95)	GB

(71) Applicant (for all designated States except US): MERCK SHARP & DOHME LIMITED [GB/GB]; Hertford Road, Hoddesdon, Hertfordshire EN11 9BU (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): HARRISON, Timothy [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). OWENS, Andrew, Pate [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB). SWAIN, Christopher, John [GB/GB]; Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

(74) Agent: HISCOCK, Ian James; Merk & Co., Inc., Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR (GB).

(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).

Published


With international search report.

(54) Title: MORPHOLINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

(57) Abstract

The present invention relates to compounds of formula (I) wherein X is -NR⁶R⁷ or C- or N-linked imidazolyl; Y is hydrogen or C₁₋₄alkyl optionally substituted by hydroxy; R¹, R², R³, R⁴ and R⁵ are selected from a variety of suitable aromatic substituents; R⁶ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by C₁₋₄alkoxy or hydroxy; R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by one or two of C₁₋₄alkoxy, hydroxy or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms

selected from N, O and S; or NR⁶R⁷ is a saturated or partially saturated heterocyclic ring of 4 to 7 ring atoms, optionally containing one of O, S, NR⁸, S(O) or S(O)₂ and optionally substituted by one or two of hydroxy, C₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR⁹ or CO₂R⁹; or NR⁶R⁷ forms a non-aromatic azabicyclic ring system of 6 to 12 ring atoms; and R^{9a} and R^{9b} are each independently hydrogen or C₁₋₄alkyl, or R^{9a} and R^{9b} are joined so, together with the carbon atoms to which they are attached, there is formed a C₅-ring; or a pharmaceutically acceptable salt thereof. The compounds are of particular use in the treatment or prevention of pain, inflammation, migraine, emesis and postherpetic neuralgia.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

MORPHOLINE DERIVATIVES AND THEIR USE AS
THERAPEUTIC AGENTS

5 This invention relates to a class of morpholine derivatives which are useful as tachykinin antagonists.

 The tachykinins are a group of naturally occurring peptides found widely distributed throughout mammalian tissues, both within the central nervous system and in peripheral nervous and circulatory systems.

10 The tachykinins are distinguished by a conserved carboxyl-terminal sequence:

Phe-X-Gly-Leu-Met-NH₂

 At present, there are three known mammalian tachykinins referred to as substance P, neurokinin A (NKA, substance K, neuromedin L) and neurokinin B (NKB, neuromedin K) (for review see J.E. Maggio, *Peptides*
15 (1985) 6(suppl. 3), 237-242). The current nomenclature designates the three tachykinin receptors mediating the biological actions of substance P, NKA and NKB as the NK₁, NK₂ and NK₃ receptors, respectively.

 Evidence for the usefulness of tachykinin receptor antagonists in pain, headache, especially migraine, Alzheimer's disease, multiple
20 sclerosis, attenuation of morphine withdrawal, cardiovascular changes, oedema, such as oedema caused by thermal injury, chronic inflammatory diseases such as rheumatoid arthritis, asthma/bronchial hyperreactivity and other respiratory diseases including allergic rhinitis, inflammatory diseases of the gut including ulcerative colitis and Crohn's disease, ocular
25 injury and ocular inflammatory diseases, proliferative vitreoretinopathy, irritable bowel syndrome and disorders of bladder function including cystitis and bladder detruser hyper-reflexia is reviewed in "Tachykinin Receptors and Tachykinin Receptor Antagonists", C.A. Maggi, R. Patacchini, P. Rovero and A. Giachetti, *J. Auton. Pharmacol.* (1993) 13,
30 23-93.


For instance, substance P is believed *inter alia* to be involved in the neurotransmission of pain sensations [Otsuka *et al*, "Role of Substance P as a Sensory Transmitter in Spinal Cord and Sympathetic Ganglia" in 1982 Substance P in the Nervous System, *Ciba Foundation Symposium* 5 91, 13-34 (published by Pitman) and Otsuka and Yanagisawa, "Does Substance P Act as a Pain Transmitter?" *TIPS* (1987) 8, 506-510], specifically in the transmission of pain in migraine (B.E.B. Sandberg *et al*, *J. Med Chem*, (1982) 25, 1009) and in arthritis [Levine *et al* in *Science* (1984) 226, 547-549]. Tachykinins have also been implicated in 10 gastrointestinal (GI) disorders and diseases of the GI tract such as inflammatory bowel disease [Mantyh *et al* in *Neuroscience* (1988) 25(3), 817-37 and D. Regoli in "Trends in Cluster Headache" Ed. Sicuteri *et al* Elsevier Scientific Publishers, Amsterdam (1987) page 85] and emesis [F. D. Tattersall *et al*, *Eur. J. Pharmacol.*, (1993) 250, R5-R6]. It is also 15 hypothesised that there is a neurogenic mechanism for arthritis in which substance P may play a role [Kidd *et al* "A Neurogenic Mechanism for Symmetrical Arthritis" in *The Lancet*, 11 November 1989 and Grönblad *et al*, "Neuropeptides in Synovium of Patients with Rheumatoid Arthritis and Osteoarthritis" in *J. Rheumatol.* (1988) 15(12), 1807-10]. Therefore, 20 substance P is believed to be involved in the inflammatory response in diseases such as rheumatoid arthritis and osteoarthritis, and fibrositis [O'Byrne *et al*, *Arthritis and Rheumatism* (1990) 33, 1023-8]. Other disease areas where tachykinin antagonists are believed to be useful are 25 allergic conditions [Hamelet *et al*, *Can. J. Pharmacol. Physiol.* (1988) 66, 1361-7], immunoregulation [Lotz *et al*, *Science* (1988) 241, 1218-21 and Kimball *et al*, *J. Immunol.* (1988) 141(10), 3564-9] vasodilation, bronchospasm, reflex or neuronal control of the viscera [Mantyh *et al*, *Proc. Natl. Acad. Sci., USA* (1988) 85, 3235-9] and, possibly by arresting or slowing β -amyloid-mediated neurodegenerative changes [Yankner *et al*, 30 *Science* (1990) 250, 279-82] in senile dementia of the Alzheimer type, Alzheimer's disease and Down's Syndrome.

Tachykinin antagonists may also be useful in the treatment of small cell carcinomas, in particular small cell lung cancer (SCLC) [Langdon *et al*, *Cancer Research* (1992) 52, 4554-7].

Substance P may also play a role in demyelinating diseases such as multiple sclerosis and amyotrophic lateral sclerosis [J. Lubner-Narod *et al*, poster *C.I.N.P. XVIIIth Congress*, 28th June-2nd July 1992], and in disorders of bladder function such as bladder detrusor hyper-reflexia (*The Lancet*, 16th May 1992, 1239).

It has furthermore been suggested that tachykinins have utility in the following disorders: depression, dysthymic disorders, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina and Reynauld's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, neuropathy, neuralgia, disorders related to immune enhancement or suppression such as systemic lupus erythmatosus (European patent specification no. 0 436 334), ophthalmic disease such as conjunctivitis, vernal conjunctivitis, and the like, and cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis (European patent specification no. 0 394 989).


European patent specification no. 0 577 394 (published 5th January 1994) discloses morpholine and thiomorpholine tachykinin receptor antagonists of the general formula



wherein R¹ is a large variety of substituents;

R^2 and R^3 are *inter alia* hydrogen;

R^4 is *inter alia*



5 R^5 is *inter alia* optionally substituted phenyl;

R^6 , R^7 and R^8 are a variety of substituents;

X is O, S, SO or SO₂;


Y is *inter alia* O; and

Z is hydrogen or C₁₋₄alkyl.

10 We have now found a further class of non-peptides which are potent antagonists of tachykinins, especially of substance P.

It is desirable that compounds may be administered orally and by injection. Certain compounds have now been discovered which act as potent non-peptide tachykinin antagonists and which, by virtue of their advantageous aqueous solubility, are particularly easily formulated for administration by both the oral and injection routes, for example in aqueous media.

The present invention provides compounds of the formula (I):



(I)

wherein

X is a group of the formula NR^6R^7 or a C- or N-linked imidazolyl ring;

5 Y is hydrogen or C_{1-4} alkyl optionally substituted by a hydroxy group;

R^1 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, CF_3 , NO_2 , CN, SR^a , SOR^a , SO_2R^a , CO_2R^a , CONR^aR^b , C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-4} alkyl substituted by C_{1-4} alkoxy, wherein R^a and R^b each independently
10 represent hydrogen or C_{1-4} alkyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy substituted by C_{1-4} alkoxy or CF_3 ;

R^3 is hydrogen, halogen or CF_3 ;

R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, CF_3 , NO_2 ,
15 CN, SR^a , SOR^a , SO_2R^a , CO_2R^a , CONR^aR^b , C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-4} alkyl substituted by C_{1-4} alkoxy, wherein R^a and R^b are as previously defined;

R^5 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy substituted by C_{1-4} alkoxy or CF_3 ;

20 R^6 is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, phenyl, or C_{2-4} alkyl substituted by C_{1-4} alkoxy or hydroxy;

R^7 is hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkyl C_{1-4} alkyl, phenyl, or C_{2-4} alkyl substituted by one or two substituents selected from C_{1-4} alkoxy, hydroxy or a 4, 5 or 6 membered heteroaliphatic ring
25 containing one or two heteroatoms selected from N, O and S;

or R^6 and R^7 , together with the nitrogen atom to which they are attached, form a saturated or partially saturated heterocyclic ring of 4 to 7 ring atoms, which ring may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR^a , S(O) or S(O)_2 and which ring
30 may be optionally substituted by one or two groups selected from

hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR^a or CO₂R^a where R^a is as previously defined;

or R⁶ and R⁷ together with the nitrogen atom to which they are attached, form a non-aromatic azabicyclic ring system of 6 to 12 ring
5 atoms;

R⁸ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;

and

R^{9a} and R^{9b} are each independently hydrogen or C₁₋₄alkyl, or R^{9a} and R^{9b} are joined so, together with the carbon atoms to which they are
10 attached, there is formed a C₆₋₇ ring;

and pharmaceutically acceptable salts thereof.

A preferred class of compounds of formula (I) is that wherein R¹ is hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halogen or CF₃.

Another preferred class of compounds of formula (I) is that wherein
15 R² is hydrogen, C₁₋₄alkyl, C₁₋₄alkoxy, halogen or CF₃.

Also preferred is the class of compounds of formula (I) wherein R³ is hydrogen, fluorine, chlorine or CF₃.

A particularly preferred class of compounds of formula (I) is that wherein R¹ is fluorine, chlorine or CF₃.

20 Another particularly preferred class of compounds of formula (I) is that wherein R² is hydrogen, fluorine, chlorine or CF₃.

Also particularly preferred is the class of compounds of formula (I) wherein R³ is hydrogen, fluorine, chlorine or CF₃.

Preferably R¹ and R² are in the 3 and 5 positions of the phenyl ring.

25 More preferably R¹ is 3-fluoro or 3-CF₃.

More preferably R² is 5-fluoro or 5-CF₃.

More preferably R³ is hydrogen.

Most preferably R¹ is 3-F or 3-CF₃, R² is 5-CF₃ and R³ is hydrogen.

A further preferred class of compound of formula (I) is that wherein

30 R⁴ is hydrogen.

Another preferred class of compounds of formula (I) is that wherein R⁵ is hydrogen, fluorine, chlorine or CF₃.

Preferably R⁴ is hydrogen and R⁵ is hydrogen or 4-fluoro.

Yet another preferred class of compounds of formula (I) is that
5 wherein R⁶ represents hydrogen, C₁₋₆alkyl or C₂₋₄alkyl substituted by C₁₋₆alkoxy.


A yet further preferred class of compounds of formula (I) is that wherein R⁷ represents hydrogen, C₁₋₆alkyl or C₂₋₄alkyl substituted by C₁₋₆alkoxy.

10 Also preferred is the class of compounds of formula (I) wherein R⁶ and R⁷, together with the nitrogen atom to which they are attached, form a saturated heterocyclic ring of 4, 5 or 6 ring atoms which may optionally contain in the ring one oxygen atom or the group NR⁸ (where R⁸ is hydrogen or methyl) and which ring may be optionally substituted by
15 hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR^a or CO₂R^a.

In particular, the group NR⁶R⁷ preferably represents NH₂, NHCH₃, N(CH₃)₂, azetidiny, morpholino, thiomorpholino, piperazino, piperidino or pyrrolidino.

Also preferred is the class of compounds of formula (I) wherein R^{9a}
20 and R^{9b} are each independently hydrogen or methyl. Preferably R^{9a} is hydrogen. Preferably R^{9b} is hydrogen. Most preferably R^{9a} and R^{9b} are both hydrogen.

From the foregoing it will be appreciated that a particularly apt
sub-group of compounds of this invention are those of the formula (Ia) and
25 pharmaceutically acceptable salts thereof:



wherein

A^1 is fluorine or CF_3 ;

A^2 is fluorine or CF_3 ;

5 A^3 is fluorine or hydrogen;

and X and Y are as defined in relation to formula (I).

A preferred group X for compounds of formula (I) or (Ia) is the NR^6R^7 group where R^6 and R^7 each independently represent hydrogen, C_{1-6} alkyl or C_{2-4} alkyl substituted by C_{1-6} alkoxy, or R^6 and R^7 , together with
 10 the nitrogen atom to which they are attached, form a saturated heterocyclic ring of 4, 5 or 6 atoms which may optionally contain in the ring one oxygen atom or the group NR^8 , where R^8 is hydrogen or methyl.

A preferred group Y for compounds of the formulae (I) or (Ia) is the methyl or CH_2OH group.

15 Where the group NR^6R^7 forms a saturated heterocyclic ring of 4 to 7 ring atoms which may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR^8 , $S(O)$ or $S(O)_2$, suitable heterocyclic groups include azetidiny, pyrrolidino, piperidino, homopiperidino, piperazino, N-methylpiperazino, morpholino and
 20 thiomorpholino.

Suitable substituents on the saturated heterocyclic ring include CH_2OH , CH_2OCH_3 , oxo, CHO , CO_2H , CO_2CH_3 , and $CO_2CH_2CH_3$.

When used herein the term "halogen" means fluorine, chlorine, bromine and iodine. The most apt halogen are fluorine and chlorine of which fluorine is preferred.

5 When used herein the term "alkyl" or "alkoxy" as a group or part of a group means that the group is straight or branched. Examples of suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl and t-butyl. Examples of suitable alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy and t-butoxy.

10 The term "alkenyl" as a group or part of a group means that the group is straight or branched and contains at least one double bond. Examples of suitable alkenyl groups include vinyl and allyl.

The term "alkynyl" as a group or part of a group means that the group is straight or branched and contains at least one triple bond. An example of a suitable alkynyl group is propargyl.

15 Suitable cycloalkyl and cycloalkyl-alkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopropylmethyl and cyclobutylmethyl.

20 Where the group NR^6R^7 represents a heteroaliphatic ring of 4 to 7 ring atoms and said ring is partially saturated, a particularly preferred group is 3-pyrroline.

Where the group NR^6R^7 represents a non-aromatic azabicyclic ring system, such a system may contain between 6 and 12, and preferably between 7 and 10, ring atoms. Suitable rings include 5-azabicyclo[2.1.1]hexyl, 5-azabicyclo[2.2.1]heptyl, 25 6-azabicyclo[3.2.1]octyl, 2-azabicyclo[2.2.2]octyl, 6-azabicyclo[3.2.2]nonyl, 6-azabicyclo[3.3.1]nonyl, 6-azabicyclo[3.2.2]decyl, 7-azabicyclo[4.3.1]decyl, 7-azabicyclo[4.4.1]undecyl and 8-azabicyclo[5.4.1]dodecyl, especially 5-azabicyclo[2.2.1]heptyl and 6-azabicyclo[3.2.1]octyl.

30 Where R^7 represents a C_{2-6} alkyl group substituted by a 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S, suitable rings include pyrrolidino, piperidino,

piperazino, morpholino, or thiomorpholino. Particularly preferred are nitrogen containing heteroaliphatic rings, especially pyrrolidino and morpholino rings.

Specific compounds within the scope of the present invention
5 include:

- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(4-morpholinobut-2-yn-yl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N-
dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;
10 4-(4-azetidinybut-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)
ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(4-imidazolylbut-2-yn-yl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
15 4-(4-(N-methylpiperazinyl)but-2-yn-yl)morpholine;
4-(4-bis(2-methoxyethyl)aminobut-2-yn-yl)-2-(R)-(1-(R)-(3,5-
bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
4-(4-pyrrolidinobut-2-yn-yl)morpholine;
20 3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)
ethoxy)-4-(4-morpholinobut-2-yn-yl)morpholine;
3-(S)-(4-fluorophenyl)-4-(4-morpholinobut-2-yn-yl)-2-(R)-(1-(R)-(3-
(trifluoromethyl)phenyl)ethoxy)morpholine;
4-(4-azetidinybut-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-
25 (trifluoromethyl)phenyl)ethoxy)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-(2-
methoxyethyl)-N-methyl)aminobut-2-yn-yl)-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-cyclopropyl-N-
(2-methoxyethyl)amino)but-2-yn-yl)-3-(S)-phenylmorpholine;
30 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-isopropyl-N-
(2-methoxyethyl)amino)but-2-yn-yl)-3-(S)-phenylmorpholine;

and pharmaceutically acceptable salts thereof.

Further preferred compounds within the scope of the present invention include:

- 5 4-(4-(N,N-dimethylamino)but-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
- 4-(4-azetidinybut-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
- 2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-4-(4-(N,N-dimethylamino)but-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;
- 10 4-(4-azetidinybut-2-yn-yl)-2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)morpholine;
- 4-(4-N-bis(2-methoxy)ethyl-N-methylamino)but-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
- 15 4-(4-(2-(S)-(methoxymethyl)pyrrolidino)but-2-yn-yl)morpholine;
- 4-(4-(7-azabicyclo[2.2.1]heptano)but-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-diisopropylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;
- 20 2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)-4-(4-(2-(S)-(methoxymethyl)pyrrolidino)but-2-yn-yl)-3-(S)-phenylmorpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-
- 4-(4-(2-(S)-(hydroxymethyl)pyrrolidino)but-2-yn-yl)morpholine;
- and pharmaceutically acceptable salts thereof.

- 25 For use in medicine, the salts of the compounds of formula (I) will be non-toxic pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds according to the invention or of their non-toxic pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention
- 30 include acid addition salts such as those formed with hydrochloric acid, fumaric acid, p-toluenesulphonic acid, maleic acid, succinic acid, acetic

acid, citric acid, tartaric acid, carbonic acid or phosphoric acid. Salts of amine groups may also comprise quaternary ammonium salts in which the amino nitrogen atom carries a suitable organic group such as an alkyl, alkenyl, alkynyl or aralkyl moiety. Furthermore, where the compounds of the invention carry an acidic moiety, suitable pharmaceutically acceptable salts thereof may include metal salts such as alkali metal salts, e.g. sodium or potassium salts; and alkaline earth metal salts, e.g. calcium or magnesium salts.

The pharmaceutically acceptable salts of the present invention may be formed by conventional means, such as by reacting the free base form of the product with one or more equivalents of the appropriate acid in a solvent or medium in which the salt is insoluble, or in a solvent such as water which is removed *in vacuo* or by freeze drying or by exchanging the anions of an existing salt for another anion on a suitable ion exchange resin.


The present invention includes within its scope prodrugs of the compounds of formula (I) above. In general, such prodrugs will be functional derivatives of the compounds of formula (I) which are readily convertible *in vivo* into the required compound of formula (I). Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elsevier, 1985.

A prodrug may be a pharmacologically inactive derivative of a biologically active substance (the "parent drug" or "parent molecule") that requires transformation within the body in order to release the active drug, and that has improved delivery properties over the parent drug molecule. The transformation *in vivo* may be, for example, as the result of some metabolic process, such as chemical or enzymatic hydrolysis of a carboxylic, phosphoric or sulphate ester, or reduction or oxidation of a susceptible functionality.

The present invention includes within its scope solvates of the compounds of formula (I) and salts thereof, for example, hydrates.

The compounds according to the invention have at least three asymmetric centres, and may accordingly exist both as enantiomers and as diastereoisomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention.

The preferred compounds of the formula (I), and (Ia) will have the 2- and 3- substituent cis and the preferred stereochemistry at the 2-position is that possessed by the compound of Example 1 (i.e. 2-(R)-), the preferred stereochemistry of the 3-position is that possessed by the compound of Example 1 (i.e. 3-(S)), and the preferred stereochemistry of the carbon to which the group Y is attached is either (R) when Y is C₁₋₄alkyl (e.g. methyl) or (S) when Y is C₁₋₄alkyl substituted by hydroxy (e.g. CH₂OH). Thus for example as shown in formula (Ib)



The present invention further provides pharmaceutical compositions comprising one or more compounds of formula (I) in association with a pharmaceutically acceptable carrier.

Preferably the compositions according to the invention are in unit dosage forms such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gums, and other pharmaceutical diluents, e.g. water, to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention, or a non-toxic pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the novel composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles. Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as

tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinyl-pyrrolidone or gelatin.

Preferred compositions for administration by injection include those comprising a compound of formula (I), as the active ingredient, in
5 association with a surface-active agent (or wetting agent or surfactant) or in the form of an emulsion (as a water-in-oil or oil-in-water emulsion).

Suitable surface-active agents include, in particular, non-ionic agents, such as polyoxyethylenesorbitans (e.g. Tween™ 20, 40, 60, 80 or 85) and other sorbitans (e.g. Span™ 20, 40, 60, 80 or 85). Compositions
10 with a surface-active agent will conveniently comprise between 0.05 and 5% surface-active agent, and preferably between 0.1 and 2.5%. It will be appreciated that other ingredients may be added, for example mannitol or other pharmaceutically acceptable vehicles, if necessary.

Suitable emulsions may be prepared using commercially available
15 fat emulsions, such as Intralipid™, Liposyn™, Infonutrol™, Lipofundin™ and Lipiphysan™. The active ingredient may be either dissolved in a pre-mixed emulsion composition or alternatively it may be dissolved in an oil (e.g. soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and an emulsion formed upon mixing with a phospholipid (e.g.
20 egg phospholipids, soybean phospholipids or soybean lecithin) and water. It will be appreciated that other ingredients may be added, for example glycerol or glucose, to adjust the tonicity of the emulsion. Suitable emulsions will typically contain up to 20% oil, for example, between 5 and 20%. The fat emulsion will preferably comprise fat droplets between 0.1
25 and 1.0µm, particularly 0.1 and 0.5µm, and have a pH in the range of 5.0 to 8.0.

Particularly preferred emulsion compositions are those prepared by mixing a compound of formula (I) with Intralipid™ or the components thereof (soybean oil, egg phospholipids, glycerol and water).

30 Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents,

or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably
5 sterile pharmaceutically acceptable solvents may be nebulised by use of inert gases. Nebulised solutions may be breathed directly from the nebulising device or the nebulising device may be attached to a face mask, tent or intermittent positive pressure breathing machine. Solution, suspension or powder compositions may be administered, preferably orally
10 or nasally, from devices which deliver the formulation in an appropriate manner.

The present invention further provides a process for the preparation of a pharmaceutical composition comprising a compound of formula (I), which process comprises bringing a compound of formula (I) into
15 association with a pharmaceutically acceptable carrier or excipient.

The compounds of formula (I) are of value in the treatment of a wide variety of clinical conditions which are characterised by the presence of an excess of tachykinin, in particular substance P, activity. These may include disorders of the central nervous system such as anxiety,
20 depression, psychosis and schizophrenia; epilepsy; neurodegenerative disorders such as dementia, including AIDS related dementia, senile dementia of the Alzheimer type, Alzheimer's disease and Down's syndrome; demyelinating diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS; Lou Gehrig's disease) and other
25 neuropathological disorders such as peripheral neuropathy, for example AIDS related neuropathy, diabetic and chemotherapy-induced neuropathy, and postherpetic and other neuralgias; neuronal damage, such as cerebral ischemic damage and cerebral edema in cerebrovascular disorders; small cell carcinomas such as small cell lung cancer; respiratory
30 diseases, particularly those associated with excess mucus secretion such as chronic obstructive airways disease, bronchopneumonia, chronic

bronchitis, asthma, and bronchospasm; airways diseases modulated by neurogenic inflammation; diseases characterised by neurogenic mucus secretion, such as cystic fibrosis; diseases associated with decreased glandular secretions, including lacrimation, such as Sjogren's syndrome, hyperlipoproteinemias IV and V, hemochromatosis, sarcoidosis, and amyloidosis; inflammatory diseases such as inflammatory bowel disease, psoriasis, fibrositis, ocular inflammation, osteoarthritis, rheumatoid arthritis, pruritis and sunburn; allergies such as eczema and rhinitis; hypersensitivity disorders such as poison ivy; ophthalmic diseases such as conjunctivitis, vernal conjunctivitis, dry eye syndrome, and the like; ophthalmic conditions associated with cell proliferation such as proliferative vitreoretinopathy; cutaneous diseases such as contact dermatitis, atopic dermatitis, urticaria, and other eczematoid dermatitis; addiction disorders including the withdrawal response produced by chronic treatment with, or abuse of, drugs such as benzodiazepines, opiates, cocaine, alcohol and nicotine; stress related somatic disorders; reflex sympathetic dystrophy such as shoulder/hand syndrome; dysthymic disorders; adverse immunological reactions such as rejection of transplanted tissues and disorders related to immune enhancement or suppression such as systemic lupus erythematosus; gastrointestinal (GI) disorders, including inflammatory disorders and diseases of the GI tract such as gastritis, gastroduodenal ulcers, gastric carcinomas, gastric lymphomas, disorders associated with the neuronal control of viscera, ulcerative colitis, Crohn's disease, irritable bowel syndrome and emesis, including acute, delayed, post-operative, late phase or anticipatory emesis such as emesis induced by chemotherapy, radiation, toxins, viral or bacterial infections, pregnancy, vestibular disorders, motion, surgery, migraine, opioid analgesics, and variations in intracranial pressure, in particular, for example, drug or radiation induced emesis or post-operative nausea and vomiting; disorders of bladder function such as cystitis, bladder detrusor hyper-reflexia and incontinence; fibrosing and collagen

diseases such as scleroderma and eosinophilic fascioliasis; disorders of blood flow caused by vasodilation and vasospastic diseases such as angina, migraine and Reynaud's disease; and pain or nociception, for example, dental pain and that attributable to or associated with any of the foregoing conditions, especially the transmission of pain in migraine.

Hence, the compounds of the present invention may be of use in the treatment of physiological disorders associated with excessive stimulation of tachykinin receptors, especially neurokinin-1 receptors, and as neurokinin-1 antagonists for the control and/or treatment of any of the aforementioned clinical conditions in mammals, including humans.

The compounds of formula (I) are also of value in the treatment of a combination of the above conditions, in particular in the treatment of combined post-operative pain and post-operative nausea and vomiting.

The compounds of formula (I) are particularly useful in the treatment of emesis, including acute, delayed, post-operative, late phase or anticipatory emesis, such as emesis or nausea induced by chemotherapy, radiation, toxins, such as metabolic or microbial toxins, viral or bacterial infections, pregnancy, vestibular disorders, motion, mechanical stimulation, gastrointestinal obstruction, reduced gastrointestinal motility, visceral pain, psychological stress or disturbance, high altitude, weightlessness, opioid analgesics, intoxication, resulting for example from consumption of alcohol, surgery, migraine, and variations in intracranial pressure. Most especially, the compounds of formula (I) are of use in the treatment of emesis induced by antineoplastic (cytotoxic) agents including those routinely used in cancer chemotherapy.

Examples of such chemotherapeutic agents include alkylating agents, for example, nitrogen mustards, ethyleneimine compounds, alkyl sulphonates and other compounds with an alkylating action such as nitrosoureas, cisplatin and dacarbazine; antimetabolites, for example, folic acid, purine or pyrimidine antagonists; mitotic inhibitors, for example,

vinca alkaloids and derivatives of podophyllotoxin; and cytotoxic antibiotics.

Particular examples of chemotherapeutic agents are described, for instance, by D. J. Stewart in *"Nausea and Vomiting: Recent Research and Clinical Advances"*, Eds. J. Kuucharczyk *et al*, CRC Press Inc., Boca Raton, Florida, USA (1991) pages 177-203, especially page 188.

Commonly used chemotherapeutic agents include cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (adriamycin), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, 5-fluorouracil, vinblastine, vincristine, bleomycin and chlorambucil [R. J. Gralla *et al* in *Cancer Treatment Reports* (1984) 68(1), 163-172].

The compounds of formula (I) are also of use in the treatment of emesis induced by radiation including radiation therapy such as in the treatment of cancer, or radiation sickness; and in the treatment of post-operative nausea and vomiting.

It will be appreciated that the compounds of formula (I) may be presented together with another therapeutic agent as a combined preparation for simultaneous, separate or sequential use for the relief of emesis. Such combined preparations may be, for example, in the form of a twin pack.

A further aspect of the present invention comprises the compounds of formula (I) in combination with a 5-HT₃ antagonist, such as ondansetron, granisetron or tropisetron, or other anti-emetic medicaments, for example, a dopamine antagonist such as metoclopramide or GABA_B receptor agonists such as baclofen. Additionally, a compound of formula (I) may be administered in combination with an anti-inflammatory corticosteroid, such as dexamethasone, triamcinolone, triamcinolone acetonide, flunisolide, budesonide, or others such as those disclosed in US patent nos. 2,789,118,

2,990,401, 3,048,581, 3,126,375, 3,929,768, 3,996,359, 3,928,326 and 3,749,712. Dexamethasone (Decadron™) is particularly preferred.

Furthermore, a compound of formula (I) may be administered in combination with a chemotherapeutic agent such as an alkylating agent, antimetabolite, mitotic inhibitor or cytotoxic antibiotic, as described above. In general, the currently available dosage forms of the known therapeutic agents for use in such combinations will be suitable.

When tested in the ferret model of cisplatin-induced emesis described by F. D. Tattersall *et al*, in *Eur. J. pharmacol.*, (1993) 250, R5-R6, the compounds of the present invention were found to attenuate the retching and vomiting induced by cisplatin.

The compounds of formula (I) are also particularly useful in the treatment of pain or nociception and/or inflammation and disorders associated therewith such as, for example, neuropathy, such as diabetic and chemotherapy-induced neuropathy, postherpetic and other neuralgias, asthma, osteoarthritis, rheumatoid arthritis, headache and especially migraine.

The present invention further provides a compound of formula (I) for use in therapy.

According to a further or alternative aspect, the present invention provides a compound of formula (I) for use in the manufacture of a medicament for the treatment of physiological disorders associated with an excess of tachykinins, especially substance P.

The present invention also provides a method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, especially substance P, which method comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound of formula (I) or a composition comprising a compound of formula (I).

For the treatment of certain conditions it may be desirable to employ a compound according to the present invention in conjunction with

another pharmacologically active agent. For example, for the treatment of respiratory diseases such as asthma, a compound of formula (I) may be used in conjunction with a bronchodilator, such as a β_2 -adrenergic receptor antagonist or tachykinin antagonist which acts at NK-2
5 receptors. The compound of formula (I) and the bronchodilator may be administered to a patient simultaneously, sequentially or in combination.

Likewise, a compound of the present invention may be employed with a leukotriene antagonists, such as a leukotriene D_4 antagonist such as a compound selected from those disclosed in European patent
10 specification nos. 0 480 717 and 0 604 114 and in US patent nos. 4,859,692 and 5,270,324. This combination is particularly useful in the treatment of respiratory diseases such as asthma, chronic bronchitis and cough.

The present invention accordingly provides a method for the
15 treatment of a respiratory disease, such as asthma, which method comprises administration to a patient in need thereof of an effective amount of a compound of formula (I) and an effective amount of a bronchodilator.

The present invention also provides a composition comprising a
20 compound of formula (I), a bronchodilator, and a pharmaceutically acceptable carrier.

It will be appreciated that for the treatment or prevention of migraine, a compound of the present invention may be used in conjunction with other anti-migraine agents, such as ergotamines or 5-HT₁ agonists,
25 especially sumatriptan.

Likewise, for the treatment of behavioural hyperalgesia, a compound of the present invention may be used in conjunction with an antagonist of N-methyl D-aspartate (NMDA), such as dizocilpine.

For the treatment or prevention of inflammatory conditions in the
30 lower urinary tract, especially cystitis, a compound of the present

invention may be used in conjunction with an antiinflammatory agent such as a bradykinin receptor antagonist.


In the treatment of the conditions associated with an excess of tachykinins, a suitable dosage level is about 0.001 to 50 mg/kg per day, in particular about 0.01 to about 25 mg/kg, such as from about 0.05 to about 10 mg/kg per day.

For example, in the treatment of conditions involving the neurotransmission of pain sensations, a suitable dosage level is about 0.001 to 25 mg/kg per day, preferably about 0.005 to 10 mg/kg per day, and especially about 0.005 to 5 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

In the treatment of emesis using an injectable formulation, a suitable dosage level is about 0.001 to 10 mg/kg per day, preferably about 0.005 to 5 mg/kg per day, and especially 0.01 to 1 mg/kg per day. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

It will be appreciated that the amount of a compound of formula (I) required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.


According to one general process (A), the compounds of formula (I) may be prepared from compounds of formula (II)



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{9a} , R^{9b} and Y are as defined in relation to formula (I) by reaction with formaldehyde followed by the desired amine of formula HNR^6R^7 , in the presence of a suitable catalyst, for example, copper (I) chloride.

This reaction may be performed in a conventional manner, for example in a solvent such as an ether, for example, dioxan, at an elevated temperature between 50°C and 100°C , for example, at about 80°C .

According to another process (B), the compounds of formula (I) may be prepared from compounds of formula (III)




wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{9a} , R^{9b} and Y are as defined in relation to formula (I) and Hal is a halogen atom such as chlorine, bromine or iodine,

by reaction with an amine of formula HNR^6R^7 or imidazole (preferably in the form of its sodium salt) in the presence of a base.

Suitable bases of use in the reaction include alkali metal carbonates such as, for example, potassium carbonate. The reaction is conveniently effected in a suitable organic solvent such as, for example, N,N-dimethylformamide, conveniently at room temperature.

According to another process (C), compounds of formula (I) may be prepared by the interconversion of a compound of formula (IV):



(IV)

10

using alkyl halides of the formula $\text{R}^6\text{-Hal}$ and $\text{R}^7\text{-Hal}$, or a suitable dihalide designed to form a saturated heterocyclic ring, wherein R^6 and R^7 are as previously defined, and Hal represents a halogen atom such as chlorine, bromine or iodine, in the presence of a base.

15

Suitable bases of use in the reaction include alkali metal carbonates, such as, for example, potassium carbonate.

20


The reaction is conveniently effected in a suitable organic solvent, such as, for example, N,N-dimethylformamide, conveniently at room temperature.

Suitable dihalides for forming a saturated heterocyclic ring include, for example, $\text{Hal-(CH}_2)_4\text{-Hal}$ (to give a pyrrolidino ring),

Hal-(CH₂)₂O(CH₂)₂Hal (to give a morpholino ring), or
Hal-(CH₂)₂NR⁸(CH₂)₂.Hal (to give a piperazino ring).


Intermediates of formula (IV) may be prepared from intermediates of formula (II) or (III) by reaction with ammonia according to the method
5 of either process (A) or process (B).

The compounds of formula (II) may be prepared from an intermediate of formula (V)



10


by reaction with a compound of formula (VI)



15


where Hal is as previously defined, in a conventional manner, for example in an organic solvent such as dimethylformamide in the presence of an acid acceptor such as potassium carbonate.

Similarly, the compounds of formula (III) may be prepared by the
20 dropwise addition of an intermediate of formula (V) to a compound or formula (VII)



where Hal is as previously defined, in the presence of a base as previously described.

The compounds of formula (V) may be prepared as shown in the following scheme in which Ar¹ represents the R¹, R², R³ substituted phenyl group; Ar² represents the R⁴, R⁵ substituted phenyl group and Ph represents phenyl:



10

The following references describe methods which may be applied by the skilled worker to the chemical synthesis set forth above once the skilled worker has read the disclosure herein.

(i) D.A. Evans *et al.*, *J. Am. Chem. Soc.*, 112, 4011 (1990).

- (ii) Yanagisawa, I. *et al.*, *J. Med. Chem.*, 27, 849 (1984).
(iii) Duschinsky, R. *et al.*, *J. Am. Chem. Soc.*, 70, 657 (1948).
(iv) Tebbe F. N. *et al.*, *J. Am. Chem. Soc.*, 100, 3611 (1978).
(v) Petasis, N. A. *et al.*, *J. Am. Chem. Soc.*, 112, 6532 (1990).
5 (vi) Takai, K. *et al.*, *J. Org. Chem.*, 52, 4412 (1987).

The Examples disclosed herein produce predominantly the preferred isomers. The unfavoured isomers are also produced on minor components. If desired they may be isolated and employed to prepare the various stereoisomers in conventional manner, for example
10 chromatography using an appropriate chiral column. However, the skilled worker will appreciate that although the Examples have been optimized to the production of the preferred isomers, variation in solvent, reagents, chromatography etc can be readily employed to yield the other isomers.

15 L-Selectride is lithium tri-sec-butylborohydride.

Where they are not commercially available, the intermediates above may be prepared by the procedures described in the accompanying Examples or by alternative procedures which will be readily apparent to one skilled in the art.

20 During any of the above synthetic sequences it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in *Protective Groups in Organic Chemistry*, ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene and
25 P.G.M. Wuts, *Protective Groups in Organic Synthesis*, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.

The exemplified compounds of this invention were tested by the methods set out at pages 36 to 39 of International Patent Specification No.
30 WO 93/01165. The compounds were found to be active with IC50 at the NK1 receptor of less than 100nM.

The following Examples illustrate the preparation of compounds according to the present invention:

DESCRIPTION 1

5 (S)-(4-Fluorophenyl)glycine

Via Chiral Synthesis:

Step A: 3-(4-Fluorophenyl)acetyl-4-(S)-benzyl-2-oxazolidinone

 An oven-dried, 1 L 3-necked flask, equipped with a septum,
10 nitrogen inlet, thermometer, and a magnetic stirring bar, was flushed
 with nitrogen and charged with a solution of 5.09g (33.0mmol) of
 4-fluorophenylacetic acid in 100ml of anhydrous ether. The solution was
 cooled to -10°C and treated with 5.60ml (40.0mmol) of triethylamine
 followed by 4.30ml (35.0mmol) of trimethylacetyl chloride. A white
15 precipitate formed immediately. The resulting mixture was stirred at
 -10°C for 40 minutes, then cooled to -78°C.

 An oven-dried, 250ml round bottom flask, equipped with a septum
 and a magnetic stirring bar, was flushed with nitrogen and charged with
 a solution of 5.31g (30.0mmol) of 4-(S)-benzyl-2-oxazolidinone in 40ml of
20 dry THF. The solution was stirred in a dry ice/acetone bath for 10
 minutes, then 18.8ml of 1.6M n-butyllithium solution in hexanes was
 slowly added. After 10 minutes, the lithiated oxazolidinone solution was
 added, via cannula, to the above mixture in the 3-necked flask. The
 cooling bath was removed from the resulting mixture and the temperature
25 was allowed to rise to 0°C. The reaction was quenched with 100ml of
 saturated aqueous ammonium chloride solution, transferred to a 1l flask,
 and the ether and THF were removed *in vacuo*. The concentrated mixture
 was partitioned between 300ml of methylene chloride and 50ml of water
 and the layers were separated. The organic layer was washed with 100ml
30 of 2N aqueous hydrochloric acid solution, 300ml of saturated aqueous
 sodium bicarbonate solution, dried over magnesium sulfate and

concentrated *in vacuo*. Flash chromatography on 400g of silica gel using 3:2 v/v hexanes/ether as the eluant afforded 8.95g of an oil that slowly solidified on standing. Recrystallisation from 10:1 hexanes/ether afforded 7.89g (83%) of the title compound as a white solid: mp 64-66°C. MS (FAB): m/z 314 ($M^+ + H$, 100%), 177 ($M - ArCH_2CO + H$, 85%). ¹H NMR (400MHz, CDCl₃) δ 2.76 (1H, dd, $J=13.2, 9.2$ Hz), 3.26 (dd, $J=13.2, 3.2$ Hz), 4.16-4.34 (4H, m), 4.65 (1H, m), 7.02-7.33 (9H, m).

Analysis Calcd. for C₁₈H₁₆FNO₃: C, 69.00; H, 5.15; N, 4.47; F, 6.06;

Found: C, 68.86; H, 5.14; N, 4.48; F, 6.08%.

Step B: 3-((S)-Azido-(4-fluorophenyl))acetyl-4-(S)-benzyl-2-oxazolidinone

An oven-dried, 1l 3-necked flask, equipped with a septum, nitrogen inlet, thermometer, and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 58.0ml of 1M potassium bis(trimethylsilyl)amide solution in toluene and 85ml of THF and was cooled to -78°C. An oven-dried 250ml round-bottomed flask, equipped with a septum and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 7.20g (23.0mmol) of 3-(4-fluorophenyl)acetyl-4-(S)-benzyl-2-oxazolidinone (from Step A) in 40ml of THF. The acyl oxazolidinone solution was stirred in a dry ice/acetone bath for 10 minutes, then transferred, via cannula, to the potassium bis(trimethylsilyl)amide solution at such a rate that the internal temperature of the mixture was maintained below -70°C. The acyl oxazolidinone flask was rinsed with 15ml of THF and the rinse was added, via cannula, to the reaction mixture and the resulting mixture was stirred at -78°C for 30 minutes. An oven-dried, 250ml round-bottomed flask, equipped with a septum and a magnetic stirring bar, was flushed with nitrogen and charged with a solution of 10.89g (35.0mmol) of 2,4,6-triisopropylphenylsulfonyl azide in 40ml of THF. The azide solution was stirred in a dry ice/acetone bath for 10 minutes, then transferred, via cannula, to the reaction mixture at such a rate that the internal

temperature of the mixture was maintained below -70°C. After 2 minutes, the reaction was quenched with 6.0ml of glacial acetic acid, the cooling bath was removed and the mixture was stirred at room temperature for 18 hours. The quenched reaction mixture was partitioned between 300ml of ethyl acetate and 300ml of 50% saturated aqueous sodium bicarbonate solution. The organic layer was separated, dried over magnesium sulfate, and concentrated *in vacuo*. Flash chromatography on 500g of silica gel using 2:1 v/v, then 1:1 v/v hexanes/methylene chloride as the eluant afforded 5.45g (67%) of the title compound as an oil. IR Spectrum (neat, cm^{-1}): 2104, 1781, 1702. ^1H NMR (400MHz, CDCl_3) δ 2.86 (1H, dd, $J=13.2$, 9.6Hz), 3.40 (1H, dd, $J=13.2$, 3.2Hz), 4.09-4.19 (2H, m), 4.62-4.68 (1H, m), 6.14 (1H, s), 7.07-7.47 (9H, m).

Analysis Calcd. for $\text{C}_{18}\text{H}_{15}\text{FN}_4\text{O}_3$: C 61.01; H, 4.27; N, 15.81; F, 5.36;
Found: C, 60.99; H, 4.19; N, 15.80; F, 5.34%.

Step C: (S)-Azido-(4-fluorophenyl)acetic acid

A solution of 5.40g (15.2mmol) of 3-((S)-azido-(4-fluorophenyl))acetyl-4-(S)-benzyl-2-oxazolidinone (from Step B) in 200ml of 3:1 v/v THF/water was stirred in an ice bath for 10 minutes. 1.28g (30.4mmol) of lithium hydroxide monohydrate was added in one portion and the resulting mixture was stirred cold for 30 minutes. The reaction mixture was partitioned between 100ml of methylene chloride and 100ml of 25% saturated aqueous sodium bicarbonate solution and the layers were separated. The aqueous layer was washed with 2 x 100ml of methylene chloride and acidified to pH 2 with 2N aqueous hydrochloric acid solution. The resulting mixture was extracted with 2 x 100ml of ethyl acetate; the extracts were combined, washed with 50ml of saturated aqueous sodium chloride solution, dried over magnesium sulfate, and concentrated *in vacuo* to afford 2.30g (77%) of the title compound as an oil that was used in the following step without further purification. IR

Spectrum (neat, cm^{-1}): 2111, 1724. ^1H NMR (400MHz, CDCl_3) δ 5.06 (1H, s), 7.08-7.45 (4H, m), 8.75 (1H, br s).

Step D: (S)-(4-Fluorophenyl)glycine

5 A mixture of 2.30g (11.8mmol) of (S)-azido-(4-fluorophenyl)acetic acid (from Step C), 2.50mg 10% palladium on carbon catalyst and 160ml 3:1 v/v water/acetic acid was stirred under an atmosphere of hydrogen for 18 hours. The reaction mixture was filtered through Celite and the flask and filter cake were rinsed well with about 1 litre of 3:1 v/v water/acetic acid. The filtrate was concentrated *in vacuo* to about 50ml of volume. 10 300ml of toluene was added and the mixture concentrated to afford a solid. The solid was suspended in 1:1 v/v methanol/ether, filtered and dried to afford 1.99g (100%) of the title compound. ^1H NMR (400MHz, $\text{D}_2\text{O} + \text{NaOD}$) δ 3.97 (1H, s), 6.77 (2H, app t, $J=8.8\text{Hz}$), 7.01 (2H, app t, $J=5.6\text{Hz}$). 15

Via Resolution:

Step A' (4-Fluorophenyl)acetyl chloride

20 A solution of 150g (0.974mol) of 4-(fluorophenyl)acetic acid and 1ml of N,N-dimethylformamide in 500ml of toluene at 40°C was treated with 20ml of thionyl chloride and heated to 40°C . An additional 61.2ml of thionyl chloride was added dropwise over 1.5 hours. After the addition, the solution was heated at 50°C for 1 hour, the solvent was removed *in vacuo* and the residual oil was distilled at reduced pressure (1.5mmHg) to 25 afford 150.4g (89.5%) of the title compound, bp = $68-70^\circ\text{C}$.

Step B': Methyl 2-bromo-3-(4-fluorophenyl)acetate

30 A mixture of 150.4g (0.872mol) of 4-(fluorophenyl)acetyl chloride (from Step A') and 174.5g (1.09mol) of bromine was irradiated at $40-50^\circ\text{C}$ with a quartz lamp for 5 hours. The reaction mixture was added dropwise to 400ml of methanol and the solution was stirred for 16 hours. The

solvent was removed *in vacuo* and the residual oil was distilled at reduced pressure (1.5mmHg) to afford 198.5g (92%) of the title compound, bp = 106-110°C.

5 **Step C': Methyl (±)-(4-fluorophenyl)glycine**

 A solution of 24.7g (0.1mol) of methyl 2-bromo-2-(4-fluorophenyl)acetate (from Step B') and 2.28g (0.01mol) of benzyl triethylammonium chloride in 25ml of methanol was treated with 6.8g (0.105mol) of sodium azide and the resulting mixture was stirred for 20
10 hours at room temperature. The reaction mixture was filtered; the filtrate was diluted with 50ml of methanol and hydrogenated in the presence of 0.5g of 10% Pd/C at 50 psi for 1 hour. The solution was filtered and the solvent removed *in vacuo*. The residue was partitioned between 10% aqueous sodium carbonate solution and ethyl acetate. The organic phase
15 was washed with water, saturated aqueous sodium chloride solution dried over magnesium sulfate and concentrated *in vacuo* to afford 9.8g of the title compound as an oil.

Step D': Methyl (S)-(4-fluorophenyl)glycinate

20 A solution of 58.4g of methyl (±) 4-(fluorophenyl)glycinate (from Step C') in 110ml of 7:1 v/v ethanol/water was mixed with a solution of 28.6g (0.0799mol) of O,O'-(+)-dibenzoyltartaric acid ((+)-DBT) (28.6g, 0.0799mol) in 110ml of 7:1 v/v ethanol:water and the resulting solution was allowed to age at room temperature. Ethyl acetate (220ml) was added
25 after crystallisation was complete and the resulting mixture was cooled to -20°C and filtered to afford 32.4g of methyl (S)-(4-fluorophenyl)glycinate, (+)-DBT salt (ee = 93.2%). The mother liquors were concentrated *in vacuo* and the free base was liberated by partitioning between ethyl acetate and aqueous sodium carbonate solution. A solution of free base, so obtained,
30 in 110ml of 7:1 v/v ethanol/water was mixed with a solution of 28.6g (0.0799mol) of O,O'-(-)-dibenzoyltartaric acid ((-)-DBT) (28.6g, 0.0799mol)

in 110ml of 7:1 v/v ethanol:water and the resulting solution was allowed to age at room temperature. Ethyl acetate (220ml) was added after
crystallisation was complete and the resulting mixture was cooled to -20°C
and filtered to afford 47.0g of methyl (R)-(4-fluorophenyl)glycinate,
5 (-)-DBT salt (ee = 75.8%). Recycling of the mother liquors and addition of
(+)-DBT gave a second crop of 7.4g of (S)-(4-fluorophenyl)glycinate,
(+)-DBT salt (ee = 96.4%). The two crops of the (S)-amino ester (39.8g)
were combined in 200ml of 7:1 v/v ethanol:water, heated for 30 minutes
and cooled to room temperature. Addition of ethyl acetate, cooling, and
10 filtration afforded 31.7g of (S)-(4-fluorophenyl)glycinate, (+)-DBT salt (ee
> 98%). Enantiomeric excess was determined by chiral HPLC (Crownpak
CR(+)) 5% MeOH in aq HClO₄ pH2 1.5ml/min 40°C 200nm).

A mixture of 17.5g of (S)-(4-fluorophenyl)glycinate, (+)-DBT salt
and 32ml of 5.5N HCl (32ml) was heated at reflux for 1.5 hours. The
15 reaction mixture was concentrated *in vacuo* and the residue was dissolved
in 40ml of water. The aqueous solution was washed (3 x 30ml of ethyl
acetate) and the layers were separated. The pH of the aqueous layer was
adjusted to 7 using ammonium hydroxide and the precipitated solid was
filtered to afford 7.4g of the title compound (ee = 98.8%).

20

DESCRIPTION 2

4-Benzyl-3-(S)-(4-fluorophenyl)-2-morpholinone

Step A: N-Benzyl-(S)-(4-fluorophenyl)glycine

25 A solution of 1.87g (11.05mmol) of (S)-(4-fluorophenyl)-glycine (from
Description 1) and 1.12ml (11.1mmol) of benzaldehyde in 11.1ml of 1N
aqueous sodium hydroxide solution and 11ml of methanol at 0°C was
treated with 165mg (4.4mmol) of sodium borohydride. The cooling bath
was removed and the resulting mixture was stirred at room temperature
30 for 30 minutes. Second portions of benzaldehyde (1.12ml (11.1mmol)) and
sodium borohydride (165mg (4.4mmol)) were added to the reaction mixture

and stirring was continued for 1.5 hours. The reaction mixture was partitioned between 100ml of ether and 50ml of water and the layers were separated. The aqueous layer was separated and filtered to remove a small amount of insoluble material. The filtrate was acidified to pH 5 with 2N aqueous hydrochloric acid solution and the solid that had precipitated was filtered, rinsed well with water, then ether, and dried to afford 1.95g of the title compound. ¹H NMR (400MHz, D₂O + NaOD) δ 3.33 (2H, AB q, J=8.4Hz), 3.85 (1H, s), 6.79-7.16 (4H, m).

10 Step B: 4-Benzyl-3-(S)-(4-fluorophenyl)-2-morpholinone

A mixture of 1.95g (7.5mmol) of N-benzyl (S)-(4-fluorophenyl)glycine, 3.90ml (22.5mmol) of N,N-diisopropyl-ethylamine, 6.50ml (75.0mmol) of 1,2-dibromoethane and 40ml of N,N-dimethylformamide was stirred at 100°C for 20 hours (dissolution of all solids occurred on warming). The reaction mixture was cooled and concentrated *in vacuo*. The residue was partitioned between 250ml of ether and 100ml of 0.5N potassium hydrogen sulfate solution and the layers were separated. The organic layer was washed with 100ml of saturated aqueous sodium bicarbonate solution, 3 x 150ml of water, dried over magnesium sulfate, and concentrated *in vacuo*. Flash chromatography on 125g of silica gel using 3:1 v/v hexanes/ether as the eluant afforded 1.58g (74%) of the title compound as an oil. ¹H NMR (400MHz, CDCl₃) δ 2.65 (1H, dt, J=3.2, 12.8Hz), 3.00 (1H, dt, J=12.8, 2.8Hz), 3.16 (1H, d, J=13.6Hz), 3.76 (1H, d, J=13.6Hz), 4.24 (1H, s), 4.37 (1H, dt, J=13.2, 3.2Hz), 4.54 (1H, dt, J=2.8, 13.2Hz), 7.07-7.56 (9H, m).

DESCRIPTION 34-Benzyl-2-(R)-(3,5-bis(trifluoromethyl)benzoyloxy)-3-(S)-(4-fluorophenyl)morpholine

5 A solution of 2.67g (10.0mmol) of 4-benzyl-3-(S)-(4-fluorophenyl)-2-morpholinone (Description 2) in 40ml of dry THF was cooled to -78°C. The cold solution was treated with 12.5ml of 1.0M L-Selectride® solution in THF, maintaining the internal reaction temperature below -70°C. The resulting solution was stirred cold for 45 minutes and the reaction was charged with 3.60ml(20.0mmol) of 3,5-bis(trifluoromethyl)benzoyl
10 chloride. The resulting yellow mixture was stirred cold for 30 minutes and the reaction was quenched with 50ml of saturated aqueous sodium bicarbonate solution. The quenched mixture was partitioned between 300ml of ether and 50ml of water and the layers were separated. The organic layer was dried over magnesium sulfate. The aqueous layer was
15 extracted with 300ml of ether; the extract was dried and combined with the original organic layer. The combined organics were concentrated *in vacuo*. Flash chromatography on 150g of silica gel using 37:3 v/v hexanes/ether as the eluant afforded 4.06g (80%) of the title compound as a solid. ¹H NMR (200MHz, CDCl₃) δ 2.50 (1H, dt, J=3.4, 12.0Hz), 2.97 (1H, app d, J=12.0Hz), 2.99 (1H, d, J=13.6Hz), 3.72-3.79 (1H, m), 3.82 (1H, d, J=2.6Hz), 4.00 (1H, d, J=13.6Hz), 4.20 (dt, J=2.4, 11.6Hz), 6.22 (1H, d, J=2.6Hz), 7.22-7.37 (7H, m), 7.57 (2H, app d, J=6.8Hz), 8.07 (1H, s), 8.47 (2H, s). MS (FAB) m/z 528 (M+H, 25%), 270 (100%).
Analysis Calcd. for C₂₆H₂₀F₇NO₃: C, 59.21; H, 3.82; N, 2.66; F, 25.21;
25 Found: C, 59.06; H, 4.05; N, 2.50; F, 25.18%.

DESCRIPTION 44-Benzyl-2-(R)-(1-(3,5-bis(trifluoromethyl)phenyl)ethenyloxy)-3-(S)-(4-fluorophenyl)morpholine

30

Step A: Dimethyl titanocene

A solution of 2.49g (10.0mmol) of titanocene dichloride in 50ml of ether in the dark at 0°C was treated with 17.5ml of 1.4M methyllithium solution in ether maintaining the internal temperature below 5°C. The resulting yellow/orange mixture was stirred at room temperature for 30 minutes and the reaction was quenched by slowly adding 25g of ice. The quenched reaction mixture was diluted with 50ml of ether and 25ml of water and the layers were separated. The organic layer was dried over magnesium sulfate and concentrated *in vacuo* to afford 2.03g (98%) of the title compound as a light-sensitive solid. The dimethyl titanocene could be stored as a solution in toluene at 0°C for at least 2 weeks without apparent chemical degradation. ¹H NMR (200MHz, CDCl₃) δ -0.15 (6H, s), 6.06 (10H, s).

Step B: 4-Benzyl-2-(R)-(1-(3,5-bis(trifluoromethyl)phenyl)ethenyloxy)-3-(S)-(4-fluorophenyl)morpholine

A solution of the compound of Description 3 (2.50g, 4.9mmol) and 2.50g (12.0mmol) of dimethyl titanocene (from Step A) in 35ml of 1:1 v/v THF/toluene was stirred in an oil bath at 80°C for 16 hours. The reaction mixture was cooled and concentrated *in vacuo*. Flash chromatography on 150g of silica gel using 3:1 v/v hexanes/methylene chloride as the eluant afforded 1.71g (69%) of the title compound as a solid. An analytical sample was obtained via recrystallisation from isopropanol: ¹H NMR (400MHz, CDCl₃) δ 2.42 (1H, dt, J=3.6, 12.0Hz), 2.90 (1H, app d, J=12.0Hz), 2.91 (1H, d, J=13.6Hz), 3.62-3.66 (1H, m), 3.72 (1H, d, J=2.6Hz), 3.94 (1H, d, J=13.6Hz), 4.09 (1H, dt, J=2.4, 12.0Hz), 4.75 (1H, d, J=3.2Hz), 4.82 (1H, d, J=3.2Hz), 5.32 (1H, d, J=2.6Hz), 7.09 (2H, t, J=8.8Hz), 7.24-7.33 (5H, m), 7.58-7.62 (2H, m), 7.80 (1H, s), 7.90 (2H, s); MS (FAB) 526 (M+H, 75%), 270 (100%).

Analysis Calcd. for C₂₇H₂₂F₇NO₂: C, 61.72; H, 4.22; N, 2.67; F, 25.31;

Found: C, 61.79; H, 4.10; N, 2.65; F, 25.27%.

DESCRIPTION 52-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

5 The compound of Description 4 (4.0g) was dissolved in ethyl acetate (50ml) and isopropanol (16ml). To this solution was added palladium on charcoal (1.5g) and the mixture was hydrogenated at 40 psi for 36h. The catalyst was removed by filtration through Celite and the solvents were removed *in vacuo*. The residue was purified by flash chromatography on silica using 100% ethyl acetate and then 1-10% methanol in ethyl acetate. 10 This afforded isomer A 500mg (15%) and isomer B 2.6g (80%) as clear oils - isomer B crystallised on standing. For the title compound: ¹H NMR (400MHz, CDCl₃) δ 1.16 (3H, d, J=6.8MHz), 1.80 (1H, br s), 3.13 (1H, dd, J=3.2, 12.4Hz), 3.23 (1H, dt, J=3.6, 12.4Hz), 3.63 (1H, dd, J=2.4, 11.2Hz), 4.01 (1H, d, J=2.4Hz), 4.13 (1H, dt, J=3.2, 12.0Hz), 4.42 (1H, d, J=2.4Hz), 15 4.19 (1H, q, J=6.8Hz), 7.04-7.09 (2H, m), 7.27-7.40 (4H, m), 7.73 (1H, s); MS (FAB) 438 (M+H, 75%), 180 (100%).

HCl salt formation. To a solution of the free base (0.77g) in diethyl ether (10ml) was added 1M-HCl in methanol (1.75ml). The solution was evaporated to dryness and on addition of diethyl ether crystals formed. 20 The solution was filtered and the residue washed with diethyl ether to give the title compound hydrochloride salt mp 248-250°C.

Analysis Calcd. for C₂₀H₁₈F₇NO₂.HCl: C, 50.70; H, 4.04; N, 2.96; Cl, 7.48; Found: C, 50.46; H, 3.85; N, 3.01; Cl, 7.31%.

25

DESCRIPTION 62-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-chlorobut-2-ynyl)-3-(S)-(4-fluorophenyl)morpholine

A solution of the product of Description 5 (free base, 5g) in N,N-dimethylformamide (20ml) was slowly added to a heated (50°C) solution of 30 1,4-dichlorobut-2-yne (2.2ml) and potassium carbonate (4.8g) in N,N-dimethylformamide (20ml). The solution was heated for a further 5h at

50°C and then the solvent removed *in vacuo*. To the residue was added water (400ml) and the product extracted into ethyl acetate (3 x 150ml). The combined organic phase was washed with water, saturated brine and dried (MgSO₄). The solvent was removed *in vacuo* and the residue chromatographed on silica gel (eluting with 10% ethyl acetate in petroleum ether bp 60-80°C) to give the title compound as a colourless oil. ¹H NMR (250MHz, CDCl₃) δ 1.41 (3H, d, J=6.6Hz), 2.80 (1H, app. t, J=10.8Hz), 2.87 (1H, td, J=3.5Hz, 11.7Hz), 3.22 (2H, t, J=1.9Hz), 3.52 (1H, d, J=2.8Hz), 3.68 (1H, d, J=1.4Hz, 11.1Hz), 4.00 (2H, t, J=1.9Hz), 4.22-4.32 (2H, m), 4.81 (1H, q, J=6.6Hz), 6.96 (2H, t, J=8.7Hz), 7.10 (2H, s), 7.31 (2H, br s), 7.56 (1H, s). m/z (CI⁺) 524 (M+H, 100%).

DESCRIPTION 7

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(prop-2-ynyl)morpholine

Propargyl bromide (1.9ml) was added to a stirred mixture of the compound of Description 5 (5g) and potassium carbonate (4.76g) in dry dimethylformamide at 23°C. After 15 min the reaction mixture was diluted with water (250ml) and extracted with ethyl acetate (3 x 100ml). The combined organic phases were washed with brine (1 x 100ml) then dried (K₂CO₃) and concentrated to leave an oil. This was purified by chromatography on silica using ethyl acetate in hexane (1:9 then 1:4) as eluent to afford the title compound as an oil. ¹H NMR (250MHz, CDCl₃) δ 1.50 (3H, d, J=6.6Hz), 2.21 (1H, s), 2.84 (1H, d, J=11.1Hz), 2.97 (1H, td, J=3.2, 11.7Hz), 3.26 (2H, d, J=1.8Hz), 3.62 (1H, d, J=2.2Hz), 3.71 (1H, dd, J=2.3, 11.1Hz), 4.33 (2H, m), 4.89 (1H, q, J=6.6Hz), 7.03 (2H, t, J=8.6Hz), 7.18 (2H, s), 7.38 (2H, br s), 7.63 (1H, s). MS (CI⁺) m/z 476 (MH, 100%).

DESCRIPTION 84-Benzyl-3-(S)-(4-fluorophenyl)-2-(R)-(3-fluoro-5-(trifluoromethyl)benzoyloxy)morpholine

The title compound was prepared from the reaction of the
5 compound of Description 2 with 3-fluoro-5-(trifluoromethyl)benzoyl
chloride according to the procedure illustrated in Description 3. ¹H NMR
(360MHz, CDCl₃) δ 2.50 (1H, dt, J=3.3, 12.0Hz), 2.96 (1H, d, J=12.0Hz),
2.98 (1H, d, J=13.6Hz), 3.75 (1H, dd, J=1.7, 11.5Hz), 3.80 (1H, d,
J=2.5Hz), 3.92 (1H, d, J=13.6Hz), 4.19 (1H, dt, J=2.1, 12.0Hz), 6.20 (1H, d,
10 J=2.5Hz), 6.99 (2H, t, J=8.7Hz), 7.2-7.37 (5H, m), 7.51-7.55 (3H, m), 7.89
(1H, d, J=8.4Hz), 8.09 (1H, s). MS (CI+) m/z 478 (M⁺+1, 100%).
Analysis Calcd. for C₂₅H₂₀F₅NO₃: C, 62.88; H, 4.23; N, 2.93;
Found: C, 62.59; H, 4.03; N, 3.07%.

15

DESCRIPTION 94-Benzyl-3-(S)-(4-fluorophenyl)-2-(R)-(1-(3-fluoro-5-(trifluoromethyl)phenyl)ethenyloxy)morpholine

The title compound was prepared in 85% yield from the compound
of Description 6 according to the procedure illustrated in Description 4.
20 ¹H NMR (360MHz, CDCl₃) δ 2.42 (1H, dt, J=3.6, 12.0Hz), 2.90 (1H, d,
J=12.0Hz), 2.91 (1H, d, J=13.6Hz), 3.60-3.62 (1H, m), 3.72 (1H, d,
J=2.6Hz), 3.92 (1H, d, J=13.6Hz), 4.09 (1H, dt, J=2.4, 12.0Hz), 4.67 (1H, d,
J=2.9Hz), 4.76 (1H, d, J=2.9Hz), 5.28 (1H, d, J=2.6Hz), 7.07 (2H, t,
J=8.7Hz), 7.2-7.37 (7H, m), 7.53 (1H, s), 7.57-7.61 (2H, m). MS (CI+) 476
25 (M+1, 100%).

DESCRIPTION 103-(S)-(4-Fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)morpholine

30

The compound of Description 9 was hydrogenated according to the
method illustrated in Description 5. This afforded a mixture of 2 epimeric

products isomer A and isomer B (the major product) as clear oils. For the title compound: ^1H NMR (360MHz, CDCl_3) δ 1.42 (3H, d, $J=6.6\text{Hz}$), 1.91 (1H, s), 3.11 (1H, dd, $J=3.2, 12.4\text{Hz}$), 3.22 (1H, dt, $J=3.6, 12.4\text{Hz}$), 3.58-3.62 (1H, m), 4.01 (1H, d, $J=2.3\text{Hz}$), 4.11 (1H, dt, $J=3.2, 12.0\text{Hz}$), 4.41 (1H, d, $J=2.3\text{Hz}$), 4.80 (1H, q, $J=6.6\text{Hz}$), 6.41 (1H, d, $J=9.2\text{Hz}$), 6.86 (1H, s), 7.02 (2H, t, $J=8.7\text{Hz}$), 7.08 (2H, d, $J=9.2\text{Hz}$), 7.21-7.26 (2H, m). MS (CI+) m/z 387 ($M+1$, 100%).

Analysis Calcd. for $\text{C}_{19}\text{H}_{18}\text{F}_6\text{NO}_2$: C, 58.91; H, 4.69; N, 3.62;
Found: C, 58.88; H, 4.81; N, 3.76%.

10

DESCRIPTION 11

4-(4-Chlorobut-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)morpholine

This compound was prepared from the compound of Description 10 following the procedure illustrated in Description 6. ^1H NMR (250MHz, CDCl_3) δ 1.43 (3H, d, $J=6.6\text{Hz}$), 2.80-2.90 (1H, m), 2.94 (1H, dt, $J=11.7, 3.5\text{Hz}$), 3.32 (2H, t, $J=2.0\text{Hz}$), 3.60 (1H, d, $J=2.8\text{Hz}$), 3.67-3.74 (1H, m), 4.14 (2H, d, $J=2.0\text{Hz}$), 4.33 (2H, dt, $J=11.3, 3.3\text{Hz}$), 4.78 (1H, q, $J=6.6\text{Hz}$), 6.39 (1H, d, $J=9.1\text{Hz}$), 6.81 (1H, s), 7.01-7.08 (3H, m), 7.36 (2H, br s). MS (CI+) m/z 474/476 ($M+1$, 100/35%).

20

DESCRIPTION 12

4-Benzyl-3-(S)-(4-fluorophenyl)-2-(R)-(3-(trifluoromethyl)benzoyloxy)morpholine

The title compound was prepared from the reaction of the compound of Description 2 with 3-(trifluoromethyl)benzoyl chloride according to the procedure illustrated in Description 3. ^1H NMR (360MHz, CDCl_3) δ 2.48 (1H, dt, $J=12.0, 3.5\text{Hz}$), 2.94 (1H, d, $J=13.6\text{Hz}$), 3.73 (1H, app.d, $J=11.4\text{Hz}$), 3.78 (1H, d, $J=2.7\text{Hz}$), 3.91 (1H, d, $J=13.6\text{Hz}$), 4.21 (1H, dt, $J=11.7, 2.4\text{Hz}$), 6.20 (1H, d, $J=2.8\text{Hz}$), 6.97 (2H, t, $J=8.7\text{Hz}$), 7.25-7.37 (5H, m), 7.53 (2H, m), 7.61 (1H, t, $J=7.8\text{Hz}$), 7.84 (1H, d,

30

J=8.0Hz), 8.21 (1H, d, J=7.8Hz), 8.30 (1H, s). MS (CI⁺) m/z 460 (M+1, 100%).

DESCRIPTION 13

5 4-Benzyl-3-(S)-(4-fluorophenyl)-2-(R)-(1-(3-(trifluoromethyl)phenyl)ethenyloxy)morpholine

10 The title compound was prepared from the compound of Description 12 according to the procedure illustrated in Description 4. ¹H NMR (360MHz, CDCl₃) δ 2.40 (1H, dt, J=11.9, 3.6Hz), 2.87 (1H, app. d, J=11.8Hz), 2.89 (1H, d, J=13.5Hz), 3.62 (1H, app.d, J=11.5Hz), 3.70 (1H, d, J=2.7Hz), 3.91 (1H, d, J=13.5Hz), 4.12 (1H, dt, J=11.7, 2.4Hz), 4.62 (1H, d, J=2.7Hz), 4.74 (1H, d, J=2.7Hz), 5.30 (1H, d, J=2.7Hz), 7.07 (2H, t, J=8.7Hz), 7.21-7.32 (5H, m), 7.40 (1H, t, J=7.8Hz), 7.53-7.63 (4H, m), 7.74 (1H, s). MS (CI⁺) m/z 458 (M+1, 100%).

15

DESCRIPTION 14

20 3-(S)-(4-Fluorophenyl)-2-(R)-(1-(R)-(3-(trifluoromethyl)phenyl)ethoxy)morpholine

25 The compound of Description 13 was hydrogenated according to the method illustrated in Description 5. This afforded a mixture of 2 epimeric products isomer A and isomer B in approximately equal mass as yellow oils. The title compound (isomer B): ¹H NMR (360MHz, CDCl₃) 1.43 (3H, d, J=6.6Hz), 3.11 (1H, dd, J=12.6, 2.9Hz), 3.22 (1H, dt, J=12.4, 3.7Hz), 3.60 (1H, dd, J=11.1, 2.8Hz), 3.99 (1H, d, J=2.2Hz), 4.13 (1H, dt, J=11.6, 3.2Hz), 4.42 (1H, d, J=2.2Hz), 4.81 (1H, q, J=6.6Hz), 6.84 (1H, d, J=7.8Hz), 6.96-7.03 (3H, m), 7.16-7.27 (3H, m), 7.38 (1H, d, J=7.5Hz). MS (CI⁺) m/z 370 (M+1, 100%).

Analysis Calcd. for C₁₉H₁₉F₄NO₂: C, 61.77; H, 5.20; N, 3.79;
Found: C, 61.60; H, 5.16; N, 3.95%.

30

DESCRIPTION 154-(4-Chlorobut-2-ynyl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-trifluoromethyl)phenyl)ethoxy)morpholine

This compound was prepared from the compound of Description 14 following the procedure illustrated in Description 6. ¹H NMR (360MHz, CDCl₃) δ 1.45 (3H, d, J=6.6Hz), 2.85 (1H, br d, J=10.5Hz), 2.93 (1H, dt, J=11.7, 3.6Hz), 3.30 (2H, d, J=1.8Hz), 3.58 (1H, d, J=2.7Hz), 3.67-3.72 (1H, m), 4.13 (2H, d, J=1.9Hz), 4.31-4.39 (2H, m), 4.79 (1H, q, J=6.6Hz), 6.81 (1H, d, J=7.8Hz), 6.97-7.05 (4H, m), 7.15 (1H, t, J=7.7Hz), 7.35 (2H, d, J=7.8Hz). MS (CI+) m/z 456/458 (M+1, 100/38%).

DESCRIPTION 164-Benzyl-3-(S)-phenyl-2-morpholinoneStep A: N-Benzyl-(S)-phenylglycine

A solution of 1.51g (10.0mmol) of (S)-phenylglycine in 5ml of 2N aqueous sodium hydroxide solution was treated with 1.0ml (10.0mmol) of benzaldehyde and stirred at room temperature for 20 minutes. The solution was diluted with 5ml of methanol, cooled to 0°C, and carefully treated with 200mg (5.3mmol) of sodium borohydride. The cooling bath was removed and the reaction mixture was stirred at room temperature for 1.5 hours. The reaction was diluted with 20ml of water and extracted with 2 x 25ml of methylene chloride. The aqueous layer was acidified with concentrated hydrochloric acid to pH 6 and the solid that precipitated was filtered, washed with 50ml of water, 50ml of 1:1 v/v methanol/ethyl ether and 50ml of ether, and dried to afford 1.83g (76%) of product, mp 230-232°C.

Analysis Calcd. for C₁₅H₁₅NO₂: C, 74.66; H, 6.27; N, 5.81;

Found: C, 74.17; H, 6.19; N, 5.86%.

Step B: 4-Benzyl-3-(S)-phenyl-2-morpholinone

A mixture of 4.00g (16.6mmol) of N-benzyl-(S)-phenylglycine (from Step A) 5.00g (36.0mmol) of potassium carbonate, 10.0ml of 1,2-dibromoethane and 25ml of N,N-dimethylformamide was stirred at 100°C for 20 hours. The mixture was cooled and partitioned between 200ml of ethyl ether and 100ml of water. The layers were separated and the organic layer was washed with 3 x 50ml of water, dried over magnesium sulfate and concentrated *in vacuo*. The residue was purified by flash chromatography on 125g of silica gel eluting with 9:1 v/v, then 4:1 hexanes/ethyl ether to afford 2.41g (54%) of the product as a solid, mp 98-100°C. ¹H NMR (250MHz, CDCl₃) δ 2.54-2.68 (1H, m), 2.96 (1H, dt, J=12.8, 2.8Hz), 3.14 (1H, d, J=13.3Hz), 3.75 (1H, d, J=13.3Hz), 4.23 (1H, s), 4.29-4.37 (1H, m), 4.53 (dt, J=3.2, 11.0Hz), 7.20-7.56 (10H, m). MS (FAB): m/z 268 (M+H; 100%).

DESCRIPTION 17

4-Benzyl-2-(R)-(3,5-bis(trifluoromethyl)benzoyloxy)-3-(S)-phenylmorpholine

A solution of 2.67g (10.0mmol) of the compound of Description 16 in 40ml of dry THF was cooled to -78°C. The cold solution was treated with 12.5ml of 1.0M L-Selectride® solution in THF, maintaining the internal reaction temperature below -70°C. The resulting solution was stirred cold for 45 minutes and the reaction was charged with 3.60ml (20.0mmol) of 3,5-bis(trifluoromethyl)benzoyl chloride. The resulting yellow mixture was stirred cold for 30 minutes and the reaction was quenched with 50ml of saturated aqueous sodium bicarbonate solution. The quenched mixture was partitioned between 300ml of ether and 50ml of water and the layers were separated. The organic layer was dried over magnesium sulfate. The aqueous layer was extracted with 300ml of ether; the extract was dried and combined with the original organic layer. The combined organics were concentrated *in vacuo*. Flash chromatography on 150g of

silica gel using 37:3 v/v hexanes/ether as the eluant afforded 4.06g (80%) of the title compound as a solid. ¹H NMR (200MHz, CDCl₃) δ 2.50 (1H, dt, J=3.4, 12.0Hz), 2.97 (1H, app d, J= 12.0Hz), 2.99 (1H, d, J=13.6Hz), 3.72-3.79 (1H, m), 3.82 (1H, d, J=2.6Hz), 4.00 (1H, d, J=13.6Hz), 4.20 (dt, J=2.4, 11.6Hz), 6.22 (1H, d, J=2.6Hz), 7.22-7.37 (7H, m), 7.57 (2H, app d, J=6.8Hz), 8.07 (1H, s), 8.47 (2H, s).

Analysis Calcd. for C₂₆H₂₁F₆NO₃: C, 61.29; H, 4.16; N, 2.75; F, 22.38;

Found: C, 61.18; H, 4.14; N, 2.70; F, 22.13%.

10

DESCRIPTION 18

4-Benzyl-2-(R)-(1-(3,5-bis(trifluoromethyl)phenyl) ethenyloxy)-3-(S)-phenylmorpholine

A solution of 2.50g (4.9mmol) of the compound of Description 17 and 2.50g (12.0mmol) of dimethyl titanocene (Description 4a), in 35ml of 1:1 v/v THF/toluene was stirred in an oil bath at 80°C for 16 hours. The reaction mixture was cooled and concentrated *in vacuo*. Flash chromatography on 150g of silica gel using 3:1 v/v hexanes/methylene chloride as the eluant afforded 1.71g (69%) of the title compound as a solid. ¹H NMR (400MHz, CDCl₃) δ 2.42 (1H, dt, J=3.6, 12.0Hz), 2.89 (app d, J=11.6Hz), 2.92 (1H, d, J=13.6Hz), 3.61-3.66 (1H, m), 3.73 (1H, d, J=2.8Hz), 4.00 (1H, d, J=13.6Hz), 4.09 (1H, dt, J=2.4, 11.6Hz), 4.75 (1H, d, J=2.8Hz), 4.79 (1H, d, J=2.8Hz), 5.36 (1H, d, J=2.4Hz), 7.23-7.41 (7H, m), 7.63 (1H, app d, J=7.2Hz), 7.79 (1H, s), 7.91 (2H, s). MS (FAB) m/z 508 (M+1, 25%).

Analysis Calcd. for C₂₇H₂₃F₆NO₂: C, 63.90; H, 4.57; N, 2.76; F, 22.46;

Found: C, 63.71; H, 4.53; N, 2.68; F, 22.66%.

30

DESCRIPTION 192-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-phenylmorpholine

5 A mixture of the compound of Description 18 (1.5g) and 10%
palladium on carbon catalyst (750mg) in a mixture of isopropanol/ethyl
acetate (25ml, 3:2 v/v) was stirred under an atmosphere of hydrogen for
48h. The catalyst was removed by filtration through celite and the
reaction flask and filter pad were rinsed with ethyl acetate (500ml). The
filtrate was concentrated *in vacuo*, flash chromatography afforded epimer
10 A (106mg) and epimer B (899mg) as clear oils. The title compound,
epimer B had the following analysis:

¹H NMR (CDCl₃, 400MHz) δ 1.46 (3H, d, J=6.8Hz), 1.92 (1H, br s), 3.13
(1H, dd, J=3.0, 12.6Hz), 3.24 (1H, dt, J=3.6, 12.6Hz), 3.62 (1H, dd, J=3.6,
11.2Hz), 4.04 (1H, d, J=2.4Hz), 4.14 (1H, dt, J=3.0, 11.2Hz), 4.48 (1H, d,
15 J=2.4Hz), 4.90 (1H, q, J=6.8Hz), 7.21-7.32 (7H, m), 7.64 (1H, s). MS (CI⁺)
m/z 420 (M⁺+1, 20%), 178 (100%).

Analysis Calcd. for C₂₀H₁₉F₆NO₂: C, 57.28; H, 4.57; N, 3.34; F, 27.18;
Found: C, 57.41; H, 4.61; N, 3.29; F, 27.23%.

20

DESCRIPTION 202-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-chlorobut-2-yn-yl)-3-(S)-phenylmorpholine

The compound of Description 19 was reacted with 1,4-dichlorobut-2-
yne following the procedure illustrated in Description 6 to afford the title
25 compound. ¹H NMR (250MHz, CDCl₃) δ 1.48 (3H, d, J=6.5Hz), 2.85-3.00
(2H, m), 3.33 (2H, br s), 3.60 (1H, d, J=2.8Hz), 3.72 (1H, br dt), 4.14 (2H, t,
J=1.75Hz), 4.31-4.41 (2H, m), 4.87 (1H, q, J=6.5Hz), 7.17 (2H, s), 7.30-7.35
(3H, m), 7.37 (2H, m), 7.61 (1H, s).

30

DESCRIPTION 214-Benzyl-2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)morpholine

The compound of Description 4 (12.8g) was dissolved in
5 tetrahydrofuran (50ml) and the mixture was cooled in ice. Borane (49ml
of 1.0M in tetrahydrofuran) was added dropwise and the reaction mixture
was stirred at room temperature for 3hr. The solution was cooled in ice
and sodium hydroxide (120ml, 1M) and hydrogen peroxide (36ml, 30 wt.
%) were added dropwise cautiously. The resulting mixture was stirred for
10 1h, then diluted with water (200ml) and extracted with ethyl acetate (3 x
50ml). The organic extracts were washed with sodium sulfite and then
brine. The organic phase was dried (MgSO₄) and evaporated to give a
clear oil. Tlc (50:50 ethyl acetate/hexane) indicated two main products
which were separated by flash chromatography on silica using a gradient
15 elution of 1-30% ethyl acetate in hexane. The minor product eluted first
(2.3g) and the major product eluted last (8g). The major product was
isolated as a white foam. ¹H NMR (360MHz, DMSO-d₆) δ 2.23-2.29 (1H,
m), 2.73 (1H, d), 2.80 (1H, d, J=13.0Hz), 3.48 (1H, d, J=3.5Hz), 3.45-3.52
(2H, m), 3.56-3.65 (2H, m), 4.00-4.06 (1H, m), 4.37 (1H, d, J=3.0Hz), 4.81
20 (1H, t, J=6.0Hz), 4.92 (1H, t, J=5.5Hz), 7.14 (2H, t, J=9.0Hz), 7.23-7.33
(5H, m), 7.35 (2H, s), 7.57 (2H, t), 7.85 (1H, s). MS (CI⁺) m/z 544 (M⁺⁺+1,
100%).

DESCRIPTION 222-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)morpholine

The compound of Description 21 (8g) was dissolved in ethyl acetate
(100ml) and isopropanol (50ml) and palladium on charcoal (1.5g) was
added to the solution. This mixture was hydrogenated at 40 psi overnight.
30 The catalyst was removed by filtration and the solvents were removed *in*
vacuo. The residue was purified by flash silica chromatography using 1-

10% methanol in dichloromethane as eluant. This afforded the product as a white powder (5.7g, 90%). ¹H NMR (360MHz, CDCl₃) δ 2.68-2.73 (1H, m), 3.03-3.15 (1H, m), 3.43-3.65 (3H, m), 3.95 (1H, d, J=3.0Hz), 4.12-4.22 (1H, m), 4.40 (1H, d, J=3.0Hz), 4.89 (1H, t, J=7.0Hz), 6.99 (t, J=9.0Hz), 7.15 (2H, s), 7.26-7.31 (1H, m), 7.62 (1H, s). MS (CI+) m/z 454 (M⁺+1, 100%).

DESCRIPTION 23

10 3-(S)-(4-Fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine

Step A: 4-Benzyl-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine

15 The compound of Description 9 (0.8g) was dissolved in tetrahydrofuran (5ml) at room temperature and borane (5ml, 1.0M in tetrahydrofuran) was added. The solution was stirred under nitrogen for 30 min until all starting material had reacted. Hydrogen peroxide (5ml, 29% aq.) and sodium hydroxide (10ml, 4N) were added dropwise to the cooled (0°C) solution with much effervescence. The resulting mixture was
20 extracted with ethyl acetate, the organic phase was washed with sodium bisulfite and brine, dried (MgSO₄) and evaporated to afford a colourless oil (1g). This material was not purified further but reacted as described in the following step.

25 Step B: 3-(S)-(4-Fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine

The compound of (a) above (1g) was dissolved in ethyl acetate/2-propanol (20ml, 3:1) and treated with Pd on carbon (100mg). The mixture was hydrogenated at 60 psi for 12h. The catalyst was removed by
30 filtration and the solvent was removed *in vacuo*. The residue was purified by medium pressure chromatography on silica (Lobar) using 5% methanol

in dichloromethane as eluant. The product was recrystallised from ether.
¹H NMR (360MHz, DMSO-d₆) δ 2.77-3.04 (3H, m), 3.36-3.51 (2H, m), 3.93
(1H, br s), 4.05-4.13 (1H, m), 4.36 (1H, d, J=2.0Hz), 4.72 (1H, t, J=5.0Hz),
4.98 (1H, t, J=7.0Hz), 6.66 (1H, d, J=9.2Hz), 6.89 (1H, s), 7.10 (2H, t,
5 J=9.0Hz), 7.33-7.37 (2H, m), 7.41 (1H, d, J=9.0Hz); MS (CI+) m/z 404
(M⁺+1, 100).

DESCRIPTION 24

10 4-(4-(Chlorobut-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-
(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine

The compound of Description 23 was reacted with 1,4-dichlorobut-2-
yne following the procedure illustrated in Description 6 to afford the title
compound. ¹H NMR (250MHz, CDCl₃) δ 2.88-3.00 (3H, m), 3.31 (2H, m),
3.64-3.76 (4H, m), 4.15 (1H, m), 4.32-4.43 (2H, m), 4.79 (1H, m), 6.43 (1H,
15 b d, J=9.1Hz), 6.79 (1H, s), 7.03-7.13 (3H, m), 7.38 (2H, m), MS (ES⁺)
m/z=490.

DESCRIPTION 25

20 2-(R)-(1-(S)-(3,5-Bis(trifluoromethyl)phenyl)-2-tert-
butyldimethylsilyloxyethoxy)-3-(S)-(4-fluorophenyl)morpholine

The product from Description 22 (2g) was dissolved in anhydrous
dichloromethane (16ml), under nitrogen, and cooled to 0°C. 2,6-Lutidine
(0.5ml) and *tert*-butyldimethyltrifluoromethane sulfonate (1.0ml) were
then added and the mixture stirred for 15 mins. The reaction mixture was
25 washed (H₂O, brine), dried (MgSO₄) and evaporated *in vacuo*. Purification
by gravity silica column using 20%-50% ethylacetate/petrol as eluant
afforded the title compound as a colourless oil. ¹H NMR (250MHz, CDCl₃)
δ -0.04 (3H, s), 0.00 (3H, s), 0.87 (9H, s), 3.15-3.36 (2H, m), 3.64-3.70 (2H,
m), 3.90-3.96 (1H, m), 4.10 (1H, d, J=2.2Hz), 4.22-4.53 (1H, m), 4.53 (1H,
30 d, J=2.2Hz), 4.91 (1H, t, J=5.9Hz), 7.04-7.14 (2H, m), 7.29-7.36 (4H, m),
7.74 (1H, br s). MS (ES⁺) m/z=567.

DESCRIPTION 26

5 2-(R)-(1-(S)-(3,5-Bis(trifluoromethyl)phenyl)-2-tert-butyl
dimethylsilyloxyethoxy)-3-(S)-(4-fluorophenyl)-4-(4-chlorobut-2-
ynyl)morpholine

The compound of Description 25 and 1,4-dichlorobut-2-yne was reacted following the procedure illustrated in Description 6 to afford the title compound as a clear oil. ¹H NMR (360MHz, CDCl₃) δ 0.00 (3H, s), 0.04 (3H, s), 0.91 (9H, s), 2.95-3.09 (2H, m), 3.40 (2H, br s), 3.72-3.83 (3H, m), 4.01 (1H, dd, J=10.2, 5.5Hz), 4.25 (2H, m), 4.50 (2H, m), 4.9 (1H, t, J=5.9Hz), 7.15 (2H, t, J=8.7Hz), 7.29 (2H, s), 7.52 (2H, br s), 7.76 (1H, s).

DESCRIPTION 27

15 4-Benzyl-2-(R)-(3-fluoro-5-(trifluoromethyl)benzoyloxy)-3-(S)-phenylmorpholine

The title compound was prepared in an analogous fashion to Description 17 using the product from Description 16 and 3-fluoro-5-(trifluoromethyl)benzoyl chloride. ¹H NMR (250MHz, CDCl₃) δ 2.47 (1H, dt, J=3.4, 12.0Hz), 2.93 (1H, s), 2.98 (1H, s), 3.72-3.80 (2H, m), 3.98 (1H, d, J=13.5Hz), 4.11-4.24 (1H, m), 7.22-7.36 (8H, m), 7.56 (3H, m), 7.89 (1H, d, J=8.0Hz), 8.10 (1H, s).

DESCRIPTION 28

25 4-Benzyl-2-(R)-(1-(3-fluoro-5-(trifluoromethyl)phenyl)ethenyloxy)-3-(S)-phenylmorpholine

The title compound was prepared as a colourless oil in an analogous fashion to Description 18 using the product from Description 27. ¹H NMR (250MHz, CDCl₃) δ 2.41 (1H, dt, J=3.6, 12.0Hz), 2.87-2.94 (2H, m), 3.62 (1H, m), 3.72 (1H, d, J=2.8Hz), 3.97-4.17 (2H, m), 7.23-7.43 (10H, m), 7.54 (1H, s), 7.63 (2H, m).

DESCRIPTION 292-(R)-(1-(R)-(3-Fluoro-5-(trifluoromethyl)phenyl)ethoxy)-3-(S)-phenylmorpholine

The title compound was prepared in an analogous fashion to Description 19 using the product from Description 28. ¹H NMR (250MHz, CDCl₃) δ 1.33 (3H, d, J=6.6Hz), 1.93 (1H, br s), 3.02-3.22 (2H, m), 3.53 (1H, m), 3.96 (1H, d, J=2.4Hz), 4.00-4.11 (1H, m), 4.38 (1H, d, J=2.4Hz), 4.75 (1H, m), 6.24 (1H, d, J=9.2Hz), 6.80 (1H, s), 6.98 (1H, d, J=8.3Hz), 7.13-7.31 (5H, m). MS (ES⁺) m/z 369.

10

DESCRIPTION 304-(4-Chlorobut-2-yn-yl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)-3-(S)-phenylmorpholine

The title compound was prepared in an analogous fashion to Description 20 using the product from Description 29. ¹H NMR (250MHz, CDCl₃) δ 1.43 (3H, d, J=6.6Hz), 2.86-2.99 (2H, m), 3.37 (2H, s), 3.61 (1H, d, J=2.6Hz), 3.68-3.73 (1H, m), 4.08-4.18 (2H, m), 4.30-4.41 (2H, m), 4.74-4.82 (1H, m), 6.26 (1H, d, J=9.09Hz), 6.84 (1H, s), 7.02 (2H, d, J=8.4Hz), 7.35 (5H, br s).

20

EXAMPLE 12-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-morpholinobut-2-yn-yl)morpholine

The compound of Description 6 (0.5g), potassium carbonate (0.4g) and morpholine (0.1g) were stirred in dry dimethylformamide under nitrogen for 5h. The mixture was partitioned between ethyl acetate and water, the organic phase was washed with brine, dried (MgSO₄) and evaporated *in vacuo*. The residue was purified on silica using ethyl acetate in petrol (1:1) followed by ethyl acetate (100%) as eluent. This afforded the title compound as a clear oil. ¹H NMR (250MHz, CDCl₃) δ 1.48 (3H, d, J=6.6Hz), 2.52 (4H, m), 2.83-3.01 (2H, m), 3.29 (4H, s), 3.59

30

(1H, d, J=2.77Hz), 3.69-3.75 (5H, m), 4.29-4.39 (2H, m), 4.88 (1H, q, J=6.5Hz), 7.0 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.36 (2H, br s), 7.63 (1H, s).
M/S (ES⁺) m/z 575 (MH⁺, 100%).

5

EXAMPLE 2

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N,N-dimethylamino)but-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine

This compound was prepared from the reaction of the compound of Description 6 and dimethylamine according to the procedure described in Example 1. ¹H NMR (250MHz, CDCl₃) δ 1.48 (3H, d, J=6.6Hz), 2.27 (6H, s), 2.84 (1H, br d), 2.98 (1H, dd, J=3.6, 11.8Hz), 3.29 (4H, m), 3.63 (1H, d, J=2.8Hz), 3.71 (1H, m), 4.34 (2H, m), 4.88 (1H, q, J=6.6Hz), 7.02 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.37 (2H, br s), 7.63 (1H, s). MS (ES⁺) m/z 533 (MH⁺, 100%).

15

EXAMPLE 3

4-(4-Azetidinyl)but-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

This compound was prepared from the reaction of the compound of Description 6 and azetidine according to the procedure described in Example 1. ¹H NMR (250MHz, CDCl₃) δ 1.47 (3H, d, J=6.6Hz), 1.99-2.10 (2H, m), 2.82-2.86 (1H, m), 2.99 (1H, dd, J=3.7, 11.9Hz), 3.21-3.32 (8H, m), 3.64 (1H, d, J=2.79Hz), 3.71 (1H, m), 4.29-4.40 (2H, m), 4.88 (1H, q, J=6.6Hz), 7.02 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.38 (2H, br s), 7.63 (1H, s).

25

EXAMPLE 4

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-(imidazolyl)but-2-yn-yl)morpholine

The compound of Description 6 was added to a solution of imidazole (77mg) and sodium hydride (42mg, 60% in oil) in dry dimethylformamide. The mixture was allowed to stir for 16h and then was partitioned between

30

water and ethyl acetate. The organic layer was washed with water, brine and dried (MgSO₄) and evaporated *in vacuo*. The compound was purified on silica using dichloromethane (100%) as eluent and gradient elution to dichloromethane/methanol/ammonia (97:2:1). This afforded the title compound as a colourless oil. ¹H NMR (250MHz, CDCl₃) δ 1.48 (3H, d, J=6.6Hz), 2.86-2.91 (3H, m), 3.30 (2H, s), 3.51 (1H, d, J=2.8Hz), 3.68-3.74 (1H, m), 4.28-4.39 (2H, m), 4.87 (1H, q, J=6.5Hz), 6.99-7.09 (4H, m), 7.16 (2H, s), 7.27 (1H, br s), 7.57 (1H, s), 7.63 (1H, s). MS (ES⁺) m/z 556 (MH⁺, 100%).

10

EXAMPLE 5

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-(N-methylpiperazinyl)but-2-yn-yl)morpholine

This compound was prepared from the reaction of the compound of Description 6 and N-methylpiperazine according to the procedure described in Example 1. ¹H NMR (250MHz, CDCl₃) δ 1.47 (3H, d, J=6.6Hz), 1.9-1.95 (2H, m), 2.30 (3H, s), 2.4-2.6 (6H, m), 2.83-2.86 (1H, m), 2.93 (1H, dt, J=12.0, 3.6Hz), 3.21-3.29 (4H, m), 3.59 (1H, d, J=3.0Hz), 3.70 (1H, d, J=12.0Hz), 4.33 (2H, q, J=12.6Hz), 4.87 (1H, q, J=6.6Hz), 7.00 (2H, t, J=7.2Hz), 7.17 (2H, s), 7.36 (2H, br m), 7.62 (1H, s).

20

EXAMPLE 6

4-(4-Bis(methoxyethyl)aminobut-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

The compound of Description 6 was reacted with bis(methoxyethyl)amine according to the procedure described in Example 1 to afford the title compound as a clear oil. ¹H NMR (360MHz, CDCl₃) δ 1.48 (3H, d, J=6.8Hz), 2.74 (4H, br m), 2.84 (1H, br d, J=12Hz), 2.95 (1H, dt, J=12.3Hz), 3.29 (2H, br s), 3.33 (6H, s), 3.49 (6H, m), 3.61 (1H, d, J=3Hz), 3.70 (1H, br d), 4.33 (2H, app. q), 4.87 (1H, q, J=6.8Hz), 7.01 (2H,

30

t, J=8.5Hz), 7.17 (2H, s), 7.36 (2H, m), 7.63 (1H, s). MS (ES) m/z 621 (M⁺+1, 100%).

EXAMPLE 7

5 2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-pyrrolidinobut-2-yn-yl)morpholine

The compound of Description 7 (0.85g), paraformaldehyde (66mg), pyrrolidine (0.18ml) and copper (I)chloride (8mg) in dioxane were heated at 80°C for 4h (*J. Med. Chem.* 1985, 28, 1760). The mixture was cooled and concentrated *in vacuo*. The residue was purified by chromatography on silica using ethyl acetate in hexane (1:4 → 100%) followed by 10% methanol in ethyl acetate as eluant. This afforded the product as a viscous oil (870mg, 87%). ¹H NMR (360MHz, CDCl₃) δ 1.47 (3H, d, J=6.6Hz), 1.80 (4H, m), 2.59 (4H, br s), 2.83 (1H, d, J=11.1Hz), 2.95 (1H, ddd, J=3.6, 11.9, 11.9Hz), 3.28 (2H, s), 3.41 (2H, s), 3.61 (1H, d, J=2.7Hz), 3.71 (1H, dd, J=2.2, 11.1Hz), 4.32 (2H, m), 4.87 (1H, q, J=6.6Hz), 7.01 (2H, t, J=8.6Hz), 7.17 (2H, s), 7.36 (2H, br s), 7.63 (1H, s). IR (film) ν - 2810 (m), 1741 (w), 1608 (m), 1510 (s), 1280 (s), 1060 (s), 900 (s), 685 (s) cm⁻¹. MS (CI⁺) m/z 559 (MH, 100%).

20

EXAMPLE 8

3-(S)-(4-Fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)-4-(4-morpholinobut-2-ynyl)morpholine

The compound of Description 11 was reacted with morpholine according to the procedure described in Example 1. ¹H NMR (360MHz, CDCl₃) δ 1.43 (3H, d, J=6.6Hz), 2.53 (4H, t, J=4.4Hz), 2.85 (1H, br d, J=10.5Hz), 2.94 (1H, dt, J=11.7, 3.5Hz), 3.31 (4H, d, J=5.5Hz), 3.60 (1H, d, J=2.8Hz), 3.66-3.76 (5H, m), 4.33 (2H, dt, J=13.3, 2.8Hz), 4.77 (1H, q, J=6.6Hz), 6.37 (1H, d, J=9.1Hz), 6.81 (1H, s), 7.00-7.07 (3H, m), 7.35 (2H, br s). MS (CI⁺) m/z 525 (M⁺+1, 98%), 524 (M⁺, 100).

30

EXAMPLE 93-(S)-(4-Fluorophenyl)-4-(4-morpholinobut-2-ynyl)-2-(R)-(1-(3-(trifluoromethyl)phenyl)ethoxy)morpholine

The compound of Description 15 was reacted with morpholine according to the procedure described in Example 1. ¹H NMR (360MHz, CDCl₃) δ 1.44 (3H, d, J=6.6Hz), 2.52 (4H, t, J=4.6Hz), 2.84 (1H, br d, J=11.6Hz), 2.94 (1H, dt, J=11.9, 3.5Hz), 3.30 (4H, dd, J=3.6, 1.4Hz), 3.58 (1H, d, J=2.8Hz), 3.66-3.75 (5H, m), 4.35 (1H, dt, J=11.7, 2.9Hz), 4.78 (1H, q, J=6.6Hz), 6.80 (1H, d, J=7.7Hz), 6.96-7.04 (3H, m), 7.15 (1H, t, J=7.7Hz), 7.35 (3H, br d, J=7.5Hz). MS (CI+) m/z 507 (M+1, 100%).

EXAMPLE 104-(4-Azetidinylbut-2-ynyl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(3-(trifluoromethyl)phenyl)ethoxy)morpholine

The compound of Description 15 was reacted with azetidine according to the procedure described in Example 1. ¹H NMR (360MHz, CDCl₃) δ 1.44 (3H, d, J=6.6Hz), 2.04 (2H, quin, J=7.1Hz), 2.84 (1H, br d, J=11.8Hz), 2.98 (1H, dt, J=11.9, 3.6Hz), 3.02-3.32 (8H, m), 3.62 (1H, d, J=2.8Hz), 3.69 (1H, m), 4.33 (1H, d, J=2.8Hz), 4.36 (1H, dt, J=11.8, 2.7Hz), 4.79 (1H, q, J=6.5Hz), 6.80 (1H, d, J=7.6Hz), 6.96-7.04 (3H, m), 7.15 (1H, t, J=7.7Hz), 7.35 (3H, br d, J=7.7Hz). MS (CI+) m/z 477 (M+1, 100%).

EXAMPLE 112-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-(2-methoxyethyl)-N-methylamino)but-2-yn-yl)-3-(S)-phenylmorpholine

The compound of Description 20 was reacted with N-(2-methoxyethyl)-N-methylamine according to the procedure described in Example 1 to afford the title compound. ¹H NMR (250MHz, CDCl₃) δ 1.48 (3H, d, J=6.5Hz), 2.33 (3H, s), 2.62 (2H, t, J=5.5Hz), 2.84 (1H, br d), 2.98 (1H, dt, J=3.5, 12.0Hz), 3.33-3.34 (2H, m), 3.35 (3H, s), 3.41 (2H, br s),

3.46 (2H, t, J=5.5Hz), 3.63 (1H, d, J=2.8Hz), 3.72 (1H, br d), 4.31-4.41 (2H, m), 4.86 (1H, q, J=6.5Hz), 7.16 (2H, s), 7.31-7.36 (3H, m), 7.36 (2H, m), 7.60 (1H, s).

5

EXAMPLE 12

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-cyclopropyl-N-(2-methoxyethyl)amino)but-2-yn-yl)-3-(S)-phenylmorpholine

The compound of Description 20 was reacted with N-cyclopropyl-N-(2-methoxyethyl)amine according to the procedure described in Example 1 to afford the title compound. ¹H NMR (360MHz, CDCl₃) δ 0.47-0.49 (4H, m), 1.48 (3H, d, J=6.5Hz), 1.94 (1H, br quin), 2.85-2.88 (3H, m), 2.98 (1H, dt, J=3.6, 12.0Hz), 3.33 (3H, s), 3.33-3.35 (2H, m), 3.47-3.52 (4H, m), 3.63 (1H, d, J=2.8Hz), 3.71 (1H, dd, J=2.0, 11.0Hz), 4.32-4.40 (2H, m), 4.86 (1H, q, J=6.5Hz), 7.16 (2H, s), 7.30-7.31 (3H, m), 7.37 (2H, m), 7.60 (1H, s).

15

EXAMPLE 13

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-isopropyl)-N-(2-methoxyethyl)amino)but-2-yn-yl)-3-(S)-phenylmorpholine

The compound of Description 20 was reacted with N-isopropyl-N-(2-methoxyethyl)amine according to the procedure described in Example 1 to afford the title compound. ¹H NMR (360MHz, CDCl₃) δ 1.06 (6H, d, J=6.0Hz), 1.47 (3H, d, J=6.5Hz), 2.72 (2H, t, J=6.0Hz), 2.82-3.00 (3H, m), 3.30-3.33 (2H, m), 3.33 (3H, s), 3.41-3.47 (4H, m), 3.61 (1H, d, J=2.5Hz), 3.71 (1H, br d), 4.32-4.39 (2H, m), 4.86 (1H, q, J=6.5Hz), 7.16 (2H, s), 7.27-7.31 (3H, m), 7.36 (2H, br s), 7.60 (1H, s).

25

30

EXAMPLE 14

4-(4-(N,N-Dimethylamino)but-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-
(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine

5 The compound of Description 24 was reacted with dimethylamine according to the procedure described in Example 1 to afford the title compound as a clear oil. ¹H NMR (360MHz, CDCl₃) δ 2.28 (6H, s), 2.88-2.97 (2H, m), 3.24 (2H, s), 3.30 (2H, d, J=9.9Hz), 3.62 (3H, m), 3.72 (1H, m), 4.35-4.23 (2H, m), 4.79 (1H, m), 6.42 (1H, d, J=8.6Hz), 6.79 (1H, s), 7.04-7.12 (3H, m), 7.38 (2H, vbr s). M/Z (ES⁺) m/z = 498.

10

EXAMPLE 15

4-(4-Azetidinylbut-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine

15 The title compound was prepared from the reaction of the compound of Description 24 and azetidine according to the procedure described in Example 1. ¹H NMR (360MHz, CDCl₃) δ 2.04 (2H, m), 2.40 (1H, vb s), 2.88-2.97 (3H, m), 3.21-3.36 (7H, m), 3.57-3.74 (4H, m), 4.35-4.42 (2H, m), 4.77-4.81 (1H, m), 6.42 (1H, d, J=8.8Hz), 6.77 (1H, s), 7.04-7.12 (3H, m), 7.38 (2H, vbr s).

20

EXAMPLE 16

2-(R)-(1-(S)-(3,5-Bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-4-(4-(N,N-dimethylamino)but-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine

25 The title compound was prepared from the reaction of the compound of Description 26 and dimethylamine according to the procedure described in Example 1. Deprotection was effected by stirring with tetrabutylammonium fluoride (1.0M) in tetrahydrofuran for 60 minutes. The mixture was partitioned between ammonium chloride solution and ethyl acetate, and the organic layer washed (H₂O, brine),
30 dried (MgSO₄) and evaporated *in vacuo*. The residue was purified on a gravity silica column using 5-10% methanol/ethyl acetate as eluant giving

the title compound as an oil. ¹H NMR (360MHz, CDCl₃) δ 2.28 (6H, s), 2.88-2.98 (2H, m), 3.21-3.34 (4H, m), 3.64-3.75 (4H, m), 4.36-4.42 (2H, m), 4.86-4.90 (1H, m), 7.05 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.39 (2H, vbr s), 7.67 (1H, s). MS (ES⁺) 549 (M+H)⁺.

5

EXAMPLE 17

4-(4-Azetidiny)but-2-yn-yl)-2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)morpholine

The title compound was prepared from the reaction of the compound of Description 26 and azetidine according to the procedure described in Example 16, which gave a white foam. ¹H NMR (250MHz, CDCl₃) δ 2.05 (2H, m), 2.37 (1H, vbr s), 2.92 (2H, m), 3.18-3.29 (8H, m), 3.66-3.76 (4H, m), 4.35-4.47 (2H, m), 4.87-4.91 (1H, m), 7.06 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.41 (2H, br s), 7.67 (1H, s). M/S (ES⁺) m/z 560.

15

EXAMPLE 18

4-(4-N-Bis(2-methoxy)ethyl-N-methylamino)but-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

The compound of Description 6 was reacted with methylaminoacetaldehyde dimethyl acetal according to the procedure described in Example 1 to afford the title compound. ¹H NMR (250MHz, CDCl₃) δ 1.48 (3H, d, J=6.6Hz), 2.36 (3H, s), 2.58 (2H, d, J=5.4Hz), 2.81-3.03 (2H, m), 3.30 (2H, m), 3.36 (6H, s), 3.43 (2H, br s), 3.61 (1H, d, J = 2.8Hz), 3.68-3.74 (1H, m), 4.29-4.40 (2H, m), 4.49 (1H, t, J=5.4Hz), 4.88 (1H, m), 7.02 (2H, t, J=8.7Hz), 7.17 (2H, s), 7.37 (2H, vbr s), 7.63 (1H, s).

25

30

EXAMPLE 19

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-(2-(S)-(methoxymethyl)pyrrolidino)but-2-yn-yl)morpholine

- 5 The compound of Description 6 was reacted with (S)(+)-2-(methoxymethyl)pyrrolidine according to the procedure described in Example 1 to afford the title compound. ¹H NMR (250MHz, CDCl₃) δ 1.48 (2H, d, J=6.6Hz), 1.70-2.05 (4H, m), 2.83-2.97 (3H, m), 3.32 (4H, br s), 3.38 (3H, s), 3.45 (1H, m), 3.58 (1H, m), 3.70-3.83 (4H, m), 4.29-4.39 (3H, m),
10 4.87 (1H, m), 7.02 (2H, t, J=8.7Hz), 7.16 (2H, s), 7.36 (2H, vbr s), 7.63 (1H, s).

EXAMPLE 20

- 4-(4-(7-Azabicyclo[2.2.1]heptano)but-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine

- 15 The compound of Description 6 was reacted with 7-azabicyclo[2.2.1]heptane hydrochloride according to the procedure described in Example 1 to afford the title compound. ¹H NMR (250MHz, CDCl₃) δ 1.30 (4H, m), 1.48 (3H, d, J=6.6Hz), 1.75 (4H, m), 2.83-
20 3.03 (2H, m), 3.17 (2H, d, J=1.8Hz), 3.27 (2H, d, J=1.3Hz), 3.37 (2H, m), 3.62 (1H, d, J=2.8Hz), 3.68-3.73 (1H, m), 4.28-4.39 (2H, m), 4.88 (1H, q, J=6.6Hz), 7.01 (2H, t, 8.7Hz), 7.17 (2H, s), 7.37 (2H, br s), 7.63 (1H, s).

EXAMPLE 21

- 25 2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-4-(4-diisopropylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine

- The compound of Description 6 was reacted with N,N-diisopropylamine according to the procedure described in Example 1 to afford the title compound. ¹H NMR (360MHz, CDCl₃) δ 1.08 (12H, d, J=4.6Hz), 1.47 (3H, d, J=4.6Hz), 2.81 (1H, br d, J=7.5Hz), 2.97 (1H, dt, J=2.6Hz, 8.3Hz), 3.16 (2H, m), 3.25 (2H, t, J=1.3Hz), 3.41 (2H, t, J=1.3Hz),
30

3.61 (1H, d, J=2.0Hz), 3.70 (1H, m), 4.27-4.37 (2H, m), 4.87 (1H, q, J=4.6Hz), 7.01 (2H, t, J=6.0Hz), 7.17 (2H, s), 7.35 (2H, br s), 7.63 (1H, s).

EXAMPLE 22

5 2-(R)-(1-(R)-(3-Fluoro-5-(trifluoromethyl)phenyl)ethoxy)-4-(4-(2-(S)-(methoxymethyl)pyrrolidino)but-2-yn-yl)-3-(S)-phenylmorpholine

The title compound was prepared from the reaction of the compound of Description 30 and 2-(S)-(methoxymethyl)pyrrolidine according to the procedure described in Example 1. ¹H NMR

10 (250MHz, CDCl₃) δ 1.43 (3H, d, J=6.60Hz), 1.90 (4H, m), 2.62 (1H, q, J=7.54Hz), 2.78-2.86 (2H, m), 2.93-3.03 (2H, m), 3.27-3.41 (7H, m), 3.58 (2H, m), 3.64 (1H, d, J=2.84Hz), 3.71 (1H, dd, J₁=1.8Hz, J₂=2.18Hz), 4.36 (1H, td, J₁=11.02Hz, J₂=2.83Hz), 4.78 (1H, q, J=6.57Hz), 6.25 (1H, d, J=9.12Hz), 6.84 (1H, s), 7.02 (1H, d, J=8.30Hz), 7.34 (5H, s).

15

EXAMPLE 23

2-(R)-(1-(R)-(3,5-Bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(2-(2-(S)-hydroxymethyl)pyrrolidino)but-2-yn-yl) morpholine

20 The title compound was prepared from the reaction of the compound of Description 6 and 2-(S)-(hydroxymethyl)pyrrolidine according to the procedure described in Example 1. ¹H NMR (250MHz, CDCl₃) δ 1.48 (3H, d, J=6.60Hz), 1.71-1.90 (4H, m), 2.18 (2H, br s), 2.61-3.06 (5H, m), 3.29 (2H, s), 3.58 (2H, m), 3.64 (1H, d, J=2.83Hz),
25 3.77 (1H, dd, J₁=11.18Hz, J₂=2.18Hz), 4.34 (2H, td, J₁=11.02Hz, J₂=2.83Hz), 4.88 (1H, q, J=6.60Hz), 7.02 (2H, t, J=8.65Hz), 7.27 (2H, s), 7.36 (2H, br s), 7.63 (1H, s). MS m/z (ES+) 589.

30 The following examples illustrate pharmaceutical compositions according to the invention.

EXAMPLE 24A Tablets containing 1-25mg of compound

		<u>Amount mg</u>		
	Compound of formula (I)	1.0	2.0	25.0
	Microcrystalline cellulose	20.0	20.0	20.0
5	Modified food corn starch	20.0	20.0	20.0
	Lactose	58.5	57.5	34.5
	Magnesium stearate	0.5	0.5	0.5

EXAMPLE 24B Tablets containing 26-100mg of compound

		<u>Amount mg</u>		
	Compound of formula (I)	26.0	50.0	100.0
	Microcrystalline cellulose	80.0	80.0	80.0
	Modified food corn starch	80.0	80.0	80.0
	Lactose	213.5	189.5	139.5
15	Magnesium stearate	0.5	0.5	0.5

The compound of formula (I), cellulose, lactose and a portion of the corn starch are mixed and granulated with 10% corn starch paste. The resulting granulation is sieved, dried and blended with the remainder of the corn starch and the magnesium stearate. The resulting granulation is then compressed into tablets containing 1.0mg, 2.0mg, 25.0mg, 26.0mg, 50.0mg and 100mg of the active compound per tablet.

EXAMPLE 25 Parenteral injection

		<u>Amount mg</u>
25	Compound of formula (I)	1 to 100mg
	Citric acid monohydrate	0.75mg
	Sodium phosphate	4.5mg
	Sodium chloride	9mg
	Water for injection	to 10ml

The sodium phosphate, citric acid monohydrate and sodium chloride are dissolved in a portion of the water. The compound of formula (I) is dissolved or suspended in the solution and made up to volume. .

5 **EXAMPLE 26 Topical formulation**

	<u>Amount mg</u>
Compound of formula (I)	1-10g
Emulsifying wax	30g
Liquid paraffin	20g
10 White soft paraffin	to 100g
The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The compound of formula (I) is added and stirring continued until dispersed. The mixture is then cooled until solid.	

15

Example 27A - (Surface-Active Agent) Injection Formulation

Compound of formula (I)	up to 10mg/kg
Tween 80™	up to 2.5%
20 [in 5% aqueous mannitol (isotonic)]	

The compound of formula (I) is dissolved directly in a solution of the commercially available Tween 80™ (polyoxyethylenesorbitan monooleate) and 5% aqueous mannitol (isotonic).

25

Example 27B - (Emulsion) Injection Formulation

Compound of formula (I)	up to 30mg/ml
Intralipid™ (10-20%)	

30

The compound of formula (I) is dissolved directly in the commercially available Intralipid™ (10 or 20%) to form an emulsion.


Example 27C - Alternative (Emulsion) Injectable Formulation

5		<u>Amount</u>
	Compound of formula (I)	0.1 - 10mg
	Soybean oil	100mg
	Egg phospholipid	6mg
	Glycerol	22mg
10	Water for injection	to 1ml

All materials are sterilized and pyrogen free. The compound of formula (I) is dissolved in soybean oil. An emulsion is then formed by mixing this solution with the egg phospholipid, glycerol and water. The emulsion is then sealed in sterile vials.

CLAIMS:

1. A compound of the formula (I):



5

wherein

X is a group of the formula NR^6R^7 or a C- or N-linked imidazolyl ring;

10 Y is hydrogen or C_{1-4} alkyl optionally substituted by a hydroxy group;

15 R^1 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, CF_3 , NO_2 , CN, SR^a , SOR^a , SO_2R^a , CO_2R^a , CONR^aR^b , C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-4} alkyl substituted by C_{1-4} alkoxy, wherein R^a and R^b each independently represent hydrogen or C_{1-4} alkyl;

R^2 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy substituted by C_{1-4} alkoxy or CF_3 ;

R^3 is hydrogen, halogen or CF_3 ;

20 R^4 is hydrogen, halogen, C_{1-6} alkyl, C_{1-6} alkoxy, hydroxy, CF_3 , NO_2 , CN, SR^a , SOR^a , SO_2R^a , CO_2R^a , CONR^aR^b , C_{2-6} alkenyl, C_{2-6} alkynyl or C_{1-4} alkyl substituted by C_{1-4} alkoxy, wherein R^a and R^b are as previously defined;

R⁵ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy substituted by C₁₋₄alkoxy or CF₃;

R⁶ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by C₁₋₄alkoxy or hydroxy;

5 R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by one or two substituents selected from C₁₋₄alkoxy, hydroxy or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;

or R⁶ and R⁷, together with the nitrogen atom to which they are
10 attached, form a saturated or partially saturated heterocyclic ring of 4 to 7 ring atoms, which ring may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR⁸, S(O) or S(O)₂ and which ring may be optionally substituted by one or two groups selected from hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR^a or CO₂R^a where R^a is as
15 previously defined;

or R⁶ and R⁷ together with the nitrogen atom to which they are attached, form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;

R⁸ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;
20 and

R^{9a} and R^{9b} are each independently hydrogen or C₁₋₄alkyl, or R^{9a} and R^{9b} are joined so, together with the carbon atoms to which they are attached, there is formed a C₅₋₇ ring;
or a pharmaceutically acceptable salt thereof.

25

2. A compound as claimed in claim 1 wherein

X is a group of the formula NR⁶R⁷ or a C- or N-linked imidazolyl ring;

Y is hydrogen or C₁₋₄alkyl optionally substituted by a hydroxy
30 group;

R¹ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, CF₃, NO₂, CN, SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by C₁₋₄alkoxy, wherein R^a and R^b each independently represent hydrogen or C₁₋₄alkyl;

5 R² is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy substituted by C₁₋₄alkoxy or CF₃;

R³ is hydrogen, halogen or CF₃;

R⁴ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, CF₃, NO₂, CN, SR^a, SOR^a, SO₂R^a, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by C₁₋₄alkoxy, wherein R^a and R^b are as previously defined;

10 R⁵ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy substituted by C₁₋₄alkoxy or CF₃;

R⁶ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by C₁₋₄alkoxy or hydroxy;

15 R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by one or two substituents selected from C₁₋₄alkoxy, hydroxy or a 4, 5 or 6 membered heteroaliphatic ring containing one or two heteroatoms selected from N, O and S;

or R⁶ and R⁷, together with the nitrogen atom to which they are attached, form a saturated or partially saturated heterocyclic ring of 4 to 7 ring atoms, which ring may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR⁸, S(O) or S(O)₂ and which ring may be optionally substituted by one or two groups selected from hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR^a or CO₂R^a where R^a is as previously defined;

20 or R⁶ and R⁷ together with the nitrogen atom to which they are attached, form a non-aromatic azabicyclic ring system of 6 to 12 ring atoms;

R⁸ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;

30 and

R^{9a} and R^{9b} are each independently hydrogen or C₁₋₄alkyl, or R^{9a} and R^{9b} are joined so, together with the carbon atoms to which they are attached, there is formed a C₅₋₇ ring;
or a pharmaceutically acceptable salt thereof.

5

3. A compound as claimed in claim 1 wherein

X is a group of the formula NR⁶R⁷ or a C- or N-linked imidazolyl ring;

10 Y is hydrogen or C₁₋₄alkyl optionally substituted by a hydroxy group;

R¹ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, CF₃, NO₂, CN, CO₂R^a, CONR^aR^b, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by C₁₋₄alkoxy, wherein R^a and R^b each independently represent hydrogen or C₁₋₄alkyl;

15 R² is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy substituted by C₁₋₄alkoxy or CF₃;

R³ is hydrogen, halogen or CF₃;

R⁴ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy, CF₃, NO₂, CN, CO₂R^a, C₂₋₆alkenyl, C₂₋₆alkynyl or C₁₋₄alkyl substituted by C₁₋₄alkoxy, wherein R^a and R^b are as previously defined;

20 R⁵ is hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkoxy substituted by C₁₋₄alkoxy or CF₃;

R⁶ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by C₁₋₄alkoxy or hydroxy;

25 R⁷ is hydrogen, C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, or C₂₋₄alkyl substituted by C₁₋₄alkoxy or hydroxy;

30 or R⁶ and R⁷, together with the nitrogen atom to which they are attached, form a saturated or partially saturated heterocyclic ring of 4 to 7 ring atoms, and which ring may optionally contain in the ring one oxygen or sulphur atom or a group selected from NR⁸, S(O) or S(O)₂ and which ring may be optionally substituted by one or two groups selected from


hydroxyC₁₋₄alkyl, C₁₋₄alkoxyC₁₋₄alkyl, oxo, COR^a or CO₂R^a where R^a is as previously defined;

R^b is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl or C₁₋₄alkoxyC₁₋₄alkyl;

and

- 5 R^{9a} and R^{9b} are each independently hydrogen or C₁₋₄alkyl, or R^{9a} and R^{9b} are joined so, together with the carbon atoms to which they are attached, there is formed a C₅₋₇ ring;
or a pharmaceutically acceptable salt thereof.

- 10 4. A compound as claimed in any one of claims 1 to 3 of formula (Ia):



- 15 wherein

A¹ is fluorine or CF₃;


A² is fluorine or CF₃;

A³ is fluorine or hydrogen; and

X and Y are as defined in relation to formula (I);

- 20 or a pharmaceutically acceptable salt thereof.

5. A compound as claimed in claim 1 or claim 2 of formula (Ib):



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^9a , R^9b , X and Y are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.

5

6. A compound as claimed in any one of claims 1 to 5 wherein X represents the NR^6R^7 group where R^6 and R^7 each independently represent hydrogen, C_{1-6} alkyl or C_{2-4} alkyl substituted by C_{1-6} alkoxy, or R^6 and R^7 , together with the nitrogen atom to which they are attached, form a saturated heterocyclic ring of 4, 5 or 6 atoms which may optionally contain in the ring one oxygen atom or the group NR^8 , where R^8 is hydrogen or methyl.

10

7. A compound as claimed in claim 6 wherein, the group NR^6R^7 represents NH_2 , $NHCH_3$, $N(CH_3)_2$, azetidiny, morpholino, thiomorpholino, piperazino, piperidino or pyrrolidino.

15

8. A compound as claimed in any one of claims 1 to 7 wherein Y represents a methyl or CH_2OH group.

20

9. A compound selected from:
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-morpholinobut-2-yn-yl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-N,N-dimethylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;

25

- 4-(4-azetidinybut-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-imidazolylbut-2-yn-yl)morpholine;
- 5 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-(N-methylpiperazinyl)but-2-yn-yl)morpholine;
- 4-(4-bis(2-methoxyethyl)aminobut-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-10 4-(4-pyrrolidinobut-2-yn-yl)morpholine;
- 3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)-4-(4-morpholinobut-2-yn-yl)morpholine;
- 3-(S)-(4-fluorophenyl)-4-(4-morpholinobut-2-yn-yl)-2-(R)-(1-(R)-(3-(trifluoromethyl)phenyl)ethoxy)morpholine;
- 15 4-(4-azetidinybut-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(R)-(3-(trifluoromethyl)phenyl)ethoxy)morpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-(2-methoxyethyl)-N-methyl)aminobut-2-yn-yl)-3-(S)-phenylmorpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-cyclopropyl-N-(2-methoxyethyl)amino)but-2-yn-yl)-3-(S)-phenylmorpholine;
- 20 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-(N-isopropyl-N-(2-methoxyethyl)amino)but-2-yn-yl)-3-(S)-phenylmorpholine;
- 4-(4-(N,N-dimethylamino)but-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
- 25 4-(4-azetidinybut-2-yn-yl)-3-(S)-(4-fluorophenyl)-2-(R)-(1-(S)-(3-fluoro-5-(trifluoromethyl)phenyl)-2-hydroxyethoxy)morpholine;
- 4-(4-N-bis(2-methoxyethyl)-N-methylamino)but-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
- 2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-30 4-(4-(2-(S)-(methoxymethyl)pyrrolidino)but-2-yn-yl)morpholine;

4-(4-(7-azabicyclo[2.2.1]heptano)but-2-yn-yl)-2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)morpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-diisopropylaminobut-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;
5 2-(R)-(1-(R)-(3-fluoro-5-(trifluoromethyl)phenyl)ethoxy)-4-(4-(2-(S)-(methoxymethyl)pyrrolidino)but-2-yn-yl)-3-(S)-phenylmorpholine;
2-(R)-(1-(R)-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(S)-(4-fluorophenyl)-4-(4-(2-(S)-(hydroxymethyl)pyrrolidino)but-2-yn-yl)morpholine;
or a pharmaceutically acceptable salt thereof.

10

10. The compound:

2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-4-(4-(N,N-dimethylamino)but-2-yn-yl)-3-(S)-(4-fluorophenyl)morpholine;
or a physiologically acceptable salt thereof.

15

11. The compound:

4-(4-azetidiny)but-2-yn-yl)-2-(R)-(1-(S)-(3,5-bis(trifluoromethyl)phenyl)-2-hydroxyethoxy)-3-(S)-(4-fluorophenyl)morpholine;
or a physiologically acceptable salt thereof.

20

12. A compound as claimed in any preceding claim for use in therapy.

13. A pharmaceutical composition comprising a compound as
25 claimed in any one of claims 1 to 11 in association with a pharmaceutically acceptable carrier or excipient.

14. A method for the treatment or prevention of physiological disorders associated with an excess of tachykinins, which method
30 comprises administration to a patient in need thereof of a tachykinin reducing amount of a compound according to claim 1, or a

pharmaceutically acceptable salt thereof, or a composition comprising a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

5 15. A method according to claim 14 for the treatment or prevention of pain or inflammation.

 16. A method according to claim 14 for the treatment or prevention of migraine.

10

 17. A method according to claim 14 for the treatment or prevention of emesis.

 18. A method according to claim 14 for the treatment or prevention of postherpetic neuralgia.

15

 19. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment or prevention of a physiological disorder associated with an excess of tachykinins.

20

 20. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment or prevention of pain or inflammation.

25 21. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment or prevention of migraine.

 22. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment or prevention of emesis.


30

23. The use of a compound as claimed in any one of claims 1 to 11 for the manufacture of a medicament for the treatment or prevention of postherpetic neuralgia.

5

24. A process for the preparation of a compound of formula (I) as claimed in claim 1, which comprises:

(A) reacting a compound of formula (II):




10

wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{9a} , R^{9b} and Y are as defined in claim 1 with formaldehyde followed by the desired amine of formula HNR^6R^7 , in the presence of a suitable catalyst; or


15

(B) reacting a compound of formula (III):



wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{9a} , R^{9b} and Y are as defined in claim 1 and Hal is a halogen atom, by reaction with an amine of formula HNR^6R^7 or
 5 imidazole, in the presence of a base; or

(C) the interconversion of a compound of formula (IV):



10 using alkyl halides of the formula R^6-Hal and R^7-Hal , or a suitable dihalide designed to form a saturated heterocyclic ring, wherein R^6 and R^7 are as defined in claim 1, and Hal represents a halogen atom, in the presence of a base;

each process being followed, where necessary, by the removal of any
 15 protecting group where present;

and when the compound of formula (I) is obtained as a mixture of enantiomers or diastereoisomers, optionally resolving the mixture to obtain the desired enantiomer;

and/or, if desired, converting the resulting compound of formula (I)
5 or a salt thereof, into a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 95/01868

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D265/32 C07D413/06 A61K31/535

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 577 394 (MERCK & CO. INC.) 5 January 1994 cited in the application see claims ---	1-24
A	EP,A,0 528 495 (MERCK SHARP & DOHME LTD.) 24 February 1993 see claims ---	1-24
P,A	WO,A,95 16679 (MERCK & CO. INC.) 22 June 1995 see claims -----	1-24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

7 November 1995

Date of mailing of the international search report

16. 11. 95

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tlx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Chouly, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB95/01868

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 14-18 are directed to a method of treatment of (diagnostic method practised on) the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/GB 95/01868

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-577394	05-01-94	AU-B- 4156893	06-01-94
		AU-B- 4656193	24-01-94
		CA-A- 2099233	30-12-93
		CN-A- 1087902	15-06-94
		CZ-A- 9403330	13-09-95
		FI-A- 946133	28-12-94
		JP-A- 6172178	21-06-94
		NO-A- 945064	28-02-95
		SI-A- 9300346	31-12-93
		WO-A- 9400440	06-01-94
		AU-B- 4160893	06-01-94
EP-A-528495	24-02-93	AU-B- 661711	03-08-95
		AU-A- 2413892	16-03-93
		CA-A- 2112397	04-03-93
		EP-A- 0600952	15-06-94
		WO-A- 9304040	04-03-93
		JP-T- 6510034	10-11-94
		US-A- 5459270	17-10-95
		ZA-A- 9206235	14-05-93
WO-A-9516679	22-06-95	AU-B- 1437595	03-07-95